Update of the Guideline on Chronic Pruritus

Developed by the Guideline Subcommittee “Chronic Pruritus” of the European Dermatology Forum

Subcommittee Members:
- Prof. Dr. Elke Weisshaar, Heidelberg (Germany)
- Prof. Dr. Erwin Tschachler, Wien (Austria)
- Prof. Dr. Johannes Ring, Munich (Germany)
- Dr. Markus Streit, Aarau (Switzerland)
- Prof. Dr. Jacek Szepietowski, Wroclaw (Poland)
- Dr. Peter Maisel, Münster (Germany)
- Prof. Dr. Malcolm Greaves (Singapore)
- Prof. Dr. Julien Lambert, Antwerp (Belgium)

Members of EDF Guideline Committee:
- Prof. Dr. Werner Aberer, Graz (Austria)
- Prof. Dr. Martine Bagot, Paris (France)
- Prof. Dr. Nicole Basset-Seguin, Paris (France)
- Prof. Dr. Ulrike Blume-Peytavi, Berlin (Germany)
- Prof. Dr. Lasse Braathen, Bern (Switzerland)
- Prof. Dr. Sergio Chimenti, Rome (Italy)
- Prof. Dr. Alexander Enk, Heidelberg (Germany)
- Prof. Dr. Claudio Feliciani, Rome (Italy)
- Prof. Dr. Claus Garbe, Tübingen (Germany)
- Prof. Dr. Harald Gollnick, Magdeburg (Germany)
- Prof. Dr. Gerd Gross, Rostock (Germany)
- Prof. Dr. Vladimir Hegyi, Bratislava (Slovakia)
- Prof. Dr. Michael Hertl, Marburg (Germany)
- Prof. Dr. Dimitrios Ioannidis, Thessaloniki (Greece)
- Prof. Dr. Gregor Jemec, Roskilde (Denmark)
- Prof. Dr. Lajos Kemény, Szeged (Hungary)
- Dr. Gudula Kirtschig (Germany)
- Prof. Dr. Robert Knobler, Wien (Austria)
- Prof. Dr. Änne-Louise Kuhn, Münster (Germany)
- Prof. Dr. Marcus Maurer, Berlin (Germany)

Chairman of EDF Guideline Committee:
PD Dr. Alexander Nast, Berlin (Germany)

Expiry date: 01/2017

EDF Guidelines Secretariat to PD Dr. Nast:
Bettina Schulze, Klinik für Dermatologie, Venerologie und Allergologie, Campus Charité Mitte, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
phone: ++49 30 450 518 062, fax: ++49 30 450 518 911, e-mail: bettina.schulze@charite.de
CONFLICT OF INTEREST STATEMENTS

The Work Under Consideration for Publication

<table>
<thead>
<tr>
<th></th>
<th>Misery, Laurent</th>
<th>Weisshaar, Elke</th>
<th>Lotti, Torello</th>
<th>Darsow, Ulf</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Grant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Consulting fee or honorarium</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Support for travel to meetings for the study or other purposes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Payment for writing or reviewing the manuscript</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Provision of writing assistance, medicines, equipment, or administrative support</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Other</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts on this study.

Relevant financial activities outside the submitted work

<table>
<thead>
<tr>
<th></th>
<th>Board membership</th>
<th>Consultancy</th>
<th>Employment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Almirall, Novartis</td>
<td>Pierre Fabre</td>
<td>University of Rome “G.Marconi”,</td>
</tr>
<tr>
<td></td>
<td>President World Health Academy Publishing House, Zurich, CH; Editor, Dermatologic Therapy; Executive, Vitiligo Research Foundation, USA</td>
<td>EV Laser, Italy; GLG, USA CLINUVEL, Australia; Applied Biology, Inc, Irvine, CA, USA; EVERETT LABORATOIRES Inc. USA; BIOSKIN EVOLUTION ©®</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Expert testimony</td>
<td>Rome, Italy</td>
<td>Advance Medical, Spain</td>
</tr>
<tr>
<td>---</td>
<td>------------------</td>
<td>------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>5</td>
<td>Grants/grants pending</td>
<td>BASF, Uriage</td>
<td>Stiefel Laboratoriums, Förderverein Juckreizforschung e.V., Fresenius</td>
</tr>
<tr>
<td>7</td>
<td>Payment for manuscript preparation</td>
<td>Pierre Fabre</td>
<td>Fresenius</td>
</tr>
<tr>
<td>8</td>
<td>Patents (planned, pending or issued)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Royalties</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Payment for development of educational presentations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Stock/stock options</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Travel/accommodations/meeting expenses unrelated to activities listed**</td>
<td>MCAS, AMEC, COSMODERM, CUTICON, MIB ESCAD, PANARAB</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Other (err on the side of full disclosure)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts.

** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

** Other relationships

<table>
<thead>
<tr>
<th>1</th>
<th>Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially</th>
</tr>
</thead>
<tbody>
<tr>
<td>influencing, what you wrote in the submitted work?</td>
<td></td>
</tr>
</tbody>
</table>
### The Work Under Consideration for Publication

<table>
<thead>
<tr>
<th></th>
<th>Ring, Johannes</th>
<th>Wallengren, Joanna</th>
<th>Tschachler, Erwin</th>
<th>Streit, Markus</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Grant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Consulting fee or honorarium</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Support for travel to meetings for the study or other purposes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Payment for writing or reviewing the manuscript</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Provision of writing assistance, medicines, equipment, or administrative support</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Other</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts on this study.

### Relevant financial activities outside the submitted work

<p>|   | Board membership |  | Consultancy | Chanel S.A. | Employment | University of Munich | Expert testimony | Grants/grants pending | ALK Abelló, Allergopharma, Almirall Hermal, Astellas, Bencard, Bogen-Idec, Galderma, Glaxo Smith-Kline, Leo, MSD, Novartis, Phadia, PLS Design, Stallergenes | Chanel S. A. | Centocor | Payment for lectures including service on speakers bureaus | Convatec, Coloplast, Johnson &amp; Johnsons, Essex |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 6 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |</p>
<table>
<thead>
<tr>
<th></th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>Payment for manuscript preparation</td>
</tr>
<tr>
<td>8</td>
<td>Patents (planned, pending or issued)</td>
</tr>
<tr>
<td>9</td>
<td>Royalties</td>
</tr>
<tr>
<td>10</td>
<td>Payment for development of educational presentations</td>
</tr>
<tr>
<td>11</td>
<td>Stock/stock options</td>
</tr>
<tr>
<td>12</td>
<td>Travel/accommodations/meeting expenses unrelated to activities listed**</td>
</tr>
<tr>
<td>13</td>
<td>Other (err on the side of full disclosure)</td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts.
** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

** Other relationships **

<table>
<thead>
<tr>
<th></th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?</td>
</tr>
</tbody>
</table>
## The Work Under Consideration for Publication

<table>
<thead>
<tr>
<th>The Work Under Consideration for Publication</th>
<th>Maisel, Peter</th>
<th>Lambert, Julien</th>
<th>Greaves, Malcolm</th>
<th>Mettag, Thomas</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Grant</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Consulting fee or honorarium</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 Support for travel to meetings for the study or other purposes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 Payment for writing or reviewing the manuscript</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Provision of writing assistance, medicines, equipment, or administrative support</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts on this study.

## Relevant financial activities outside the submitted work

<table>
<thead>
<tr>
<th>Relevant financial activities outside the submitted work</th>
<th>Maisel, Peter</th>
<th>Lambert, Julien</th>
<th>Greaves, Malcolm</th>
<th>Mettag, Thomas</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Board membership</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Consultancy</td>
<td>MEDA, PFIZER, MSD, ABBVIE, JANSEN-CILAG, LEO PHARMA</td>
<td></td>
<td></td>
<td>FMC Germany</td>
</tr>
<tr>
<td>3 Employment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 Expert testimony</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 Grants/grants pending</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 Payment for lectures including service on speakers bureaus</td>
<td>GSK, MEDA, PFIZER, MSD, ABBVIE, JANSEN-CILAG, LEO PHARMA</td>
<td></td>
<td></td>
<td>FMC Germany Roche</td>
</tr>
<tr>
<td>7 Payment for manuscript preparation</td>
<td></td>
<td></td>
<td></td>
<td>FMC Germany</td>
</tr>
<tr>
<td>8 Patents (planned, pending or issued)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 Royalties</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 Payment for development of</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>educational presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 Stock/stock options</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 Travel/accommodations/meeting expenses unrelated to activities listed**</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13 Other (err on the side of full disclosure)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts.
** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

**Other relationships**

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Conflicts of Interests

### The Work Under Consideration for Publication

<table>
<thead>
<tr>
<th>1</th>
<th>Grant</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Consulting fee or honorarium</td>
</tr>
<tr>
<td>3</td>
<td>Support for travel to meetings for the study or other purposes</td>
</tr>
<tr>
<td>4</td>
<td>Fees for participation in review activities, such as data monitoring boards, statistical analysis, end point committees, and the like</td>
</tr>
<tr>
<td>5</td>
<td>Payment for writing or reviewing the manuscript</td>
</tr>
<tr>
<td>6</td>
<td>Provision of writing assistance, medicines, equipment, or administrative support</td>
</tr>
<tr>
<td>7</td>
<td>Other</td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts on this study.

### Relevant financial activities outside the submitted work

<table>
<thead>
<tr>
<th>1</th>
<th>Board membership</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Consultancy</td>
</tr>
<tr>
<td>3</td>
<td>Employment</td>
</tr>
<tr>
<td>4</td>
<td>Expert testimony</td>
</tr>
<tr>
<td>5</td>
<td>Grants/grants pending</td>
</tr>
<tr>
<td>6</td>
<td>Payment for lectures including service on speakers bureaus</td>
</tr>
<tr>
<td>7</td>
<td>Payment for manuscript preparation</td>
</tr>
<tr>
<td>8</td>
<td>Patents (planned, pending or issued)</td>
</tr>
<tr>
<td>9</td>
<td>Royalties</td>
</tr>
<tr>
<td>10</td>
<td>Payment for</td>
</tr>
<tr>
<td></td>
<td>development of educational presentations</td>
</tr>
<tr>
<td>---</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>11</td>
<td>Stock/stock options</td>
</tr>
<tr>
<td>12</td>
<td>Travel/accommodations/meeting expenses unrelated to activities listed**</td>
</tr>
<tr>
<td>13</td>
<td>Other (err on the side of full disclosure)</td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts.
** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

**Other relationships**

<table>
<thead>
<tr>
<th></th>
<th>Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
</table>
European Guideline on Chronic Pruritus

In cooperation with the European Dermatology Forum (EDF) and the European Academy of Dermatology and Venereology (EADV)

E Weisshaar¹, JC Szepietowski², U Darsow³, L Misery⁴, J Wallengren⁵, T Mettang⁶, U Gieler⁷, T Lotti⁸, J Lambert⁹, P Maisel¹⁰, M Streit¹¹, M Greaves¹², E Tschachler¹³, J Ring³, S Ständer¹⁴

Department of Clinical Social Medicine, Environmental and Occupational Dermatology, Ruprecht-Karls-University Heidelberg, Germany¹, Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Poland², Department of Dermatology and Allergy Biederstein, Technical University München and ZAUM - Center for Allergy and Environment, Munich, Germany³, Department of Dermatology, University Hospital Brest, France⁴, Department of Dermatology, Lund University, Sweden⁵, German Clinic for Diagnostics, Nephrology, Wiesbaden, Germany⁶, Department of Psychosomatic Dermatology, Clinic for Psychosomatic Medicine, University of Giessen, Germany⁷, Department of Dermatology, University of Rome “G. Marconi”, Italy⁸, Department of Dermatology, University of Antwerpen, Belgium⁹, Department of General Medicine, University Hospital Muenster, Germany¹⁰, Department of Dermatology, Kantonsspitale Aarau, Switzerland¹¹, Department of Dermatology, St. Thomas Hospital Lambeth, London, UK¹², Department of Dermatology, Medical University Vienna, Austria¹³, Department of Dermatology, Competence Center for Pruritus, University Hospital Muenster, Germany¹⁴

Corresponding authors:
Sonja Ständer M.D.
Competence Center Chronic Pruritus
Dept. of Dermatology
University Hospital Münster
Von-Esmarch-Str. 58
D-48149 Münster, Germany
Tel: 0049-251-8356534
Fax: 0049-251-8352559
Email: sonja.staender@uni-muenster.de

Elke Weisshaar M.D.
Dept. Clinical Social Medicine, Occupational and Environmental Dermatology
Ruprecht-Karls-University Heidelberg
Thibautstr. 3
D-69115 Heidelberg, Germany
Tel: 0049-6221-568752
Fax: 0049-6221-565584
Email: elke.weisshaar@med.uni-heidelberg.de
Abbreviations and Explanations

AD   Atopic Dermatitis
AEP  Atopic eruption of pregnancy
CGRP Calcitonin gene-related peptide
CKD  Chronic kidney disease
CP   Chronic pruritus (longer than 6 weeks)
DIF  Direct immunofluorescence
ICP  Intrahepatic cholestasis of pregnancy
IFSI International Forum on the Study of Itch
IIF  Indirect immunofluorescence
IL   Interleukin
Itch Synonymous with pruritus
NSAID Non-steroidal anti-inflammatory drugs
PAR  Proteinase-activated receptor
PBC  Primary biliary cirrhosis
PEP  Polymorphic eruption of pregnancy
PG   Pemphigoid gestationis
PN   Prurigo nodularis
Pruritus A skin sensation which elicits the urge to scratch
PUO  Pruritus of unknown origin
PTH  Parathyroid hormone
PV   Polycythaemia vera
RCT  Randomized controlled trials
SSRI Selective serotonin re-uptake inhibitors
TRP  Transient receptor potential
UV   Ultraviolet
VIP  Vasoactive intestinal peptide
The clinical picture of chronic pruritus............................................................................. 16
4.1.1 Pruritus in inflamed skin and non-inflamed skin .................................................. 16
4.1.2 Pruritus in kidney disease ................................................................................... 16
4.1.3 Pruritus in hepatic diseases ................................................................................. 16
4.1.4 Pruritus in metabolic and endocrine diseases ...................................................... 17
4.1.5 Pruritus in malignancies ..................................................................................... 17
4.1.6 Pruritus in infectious diseases .......................................................................... 18
4.1.7 Pruritus in neurological diseases ....................................................................... 18
4.1.8 Drug induced chronic pruritus .......................................................................... 18
4.2 Specific patient populations .................................................................................. 19
4.2.1 Chronic pruritus in the elderly ........................................................................... 19
4.2.2 Chronic pruritus in pregnancy .......................................................................... 19
4.2.3 Chronic pruritus in children .............................................................................. 20
5. Diagnostic management ......................................................................................... 21
5.1 Patient’s history, examination and clinical characteristics of pruritus .................... 21
5.2 Diagnostic algorithm and Diagnostics .................................................................. 23
6. Therapy .................................................................................................................. 23
6.1 Therapy: General principles .................................................................................. 23
6.2 Causative therapy and etiology specific treatment ................................................ 24
6.3. Symptomatic therapy: topical .............................................................................. 24
6.3.1 Local anaesthetics ............................................................................................ 24
6.3.2 Glucocorticosteroids ....................................................................................... 25
6.3.3. Capsaicin ....................................................................................................... 25
6.3.4. Cannabinoid receptor agonists ....................................................................... 27
6.3.5 Tacrolimus and Pimecrolimus ....................................................................... 27
6.3.6 Acetylsalicylic Acid ......................................................................................... 28
6.3.7 Zinc, Menthol and Camphor .......................................................................... 28
6.3.8 Gabapentin and Pregabalin ............................................................................ 30
6.3.9 Mast cell inhibitors ......................................................................................... 30
6.3.10 Leukotriene receptor antagonist, TNF antagonists ......................................... 31
6.3.11 Thalidomide .................................................................................................. 32
6.3.12 Serotonin receptor antagonists ...................................................................... 32
6.3.13 Gabapentin and Pregabalin .......................................................................... 33
6.3.14 Antidepressants ............................................................................................. 34
6.3.15 Gabapentin and Pregabalin .......................................................................... 35
6.3.16 Thalidomide .................................................................................................. 35
6.3.17 Leukotriene receptor antagonist, TNF antagonists ......................................... 36
6.3.18 Thalidomide .................................................................................................. 36
6.3.19 Gabapentin and Pregabalin .......................................................................... 37
6.3.20 Antidepressants ............................................................................................. 37
6.4 Systemic Therapy ................................................................................................... 30
6.4.1 Antihistamines ................................................................................................ 30
6.4.2 Mast cell inhibitors ......................................................................................... 31
6.4.3 Glucocorticosteroids ....................................................................................... 32
6.4.4 Opioid receptor agonists and antagonists ....................................................... 32
6.4.5 Gabapentin and Pregabalin ............................................................................ 33
6.5 UV Phototherapy .................................................................................................. 37
6.6 Psychosomatic therapy (Relaxation techniques and psychotherapy) .................... 39
7. Key summary of discussion concerning country-specific procedures .................... 40
8. References ............................................................................................................... 55
1 The challenge of writing this guideline

Chronic pruritus (CP) is a frequent symptom in the general population and in many skin and systemic diseases (Weisshaar and Dalgard 2009). Its frequency demonstrates a high burden and an impaired quality of life. This guideline addresses a symptom and not a disease. As a consequence of the diversity of possible underlying diseases, no single therapy concept can be recommended. Each form of pruritus has to be considered individually. There is still a significant lack of randomized controlled trials (RCT), which can be explained by the diversity and complexity of this symptom, multifactorial aetiologies of pruritus and the lack of well-defined outcome measures. To complicate matters, RCT exist for some types of pruritus, but with conflicting results. However, new therapies for improved medical care have been suggested. In addition, many expert recommendations are provided. The health care system in many countries and their social economic situation with constantly reducing financial resources increases the need for guidelines. These recommendations are based on a consensus of participating countries, while also allowing for country-specific treatment modalities, and health care structures. Furthermore, it should be appreciated that some topical and systemic therapies can only be prescribed “off-label” and require informed consent. If such “off-label” therapies cannot be initiated in the physician’s office, cooperation with a specialised centre for pruritus might be helpful.

This guideline addresses all medical disciplines that work with patients suffering from chronic pruritus (CP). This includes also entities defined by chronic scratch lesions such as prurigo nodularis and lichen simplex. They are not only focussed on dermatology.

2 Definitions and clinical classification

The definitions presented in this guideline are based on a consensus among the European participants; however, some of them have provoked controversy. Most of the contributors accept pruritus and itch to be synonymous. A practical distinction is that between acute pruritus and chronic forms (lasting six weeks or longer). Pruritus / itch is a sensation that provokes the desire to scratch. According to the International Forum on the Study of Itch (IFSI), CP is defined as pruritus
lasting 6 weeks or longer (Stander, Weisshaar et al. 2007). Following the IFSI, the term “pruritus sine materia” will not be used in this guideline (Stander, Weisshaar et al. 2006). In patients with no identified underlying disease, the term “pruritus of unknown origin” or “pruritus of undetermined origin” (PUO) is used. The term “pruritus of unknown etiology” should be avoided as in most clinically well-defined forms of pruritus the mechanism is unknown (e.g. chronic kidney disease (CKD) associated pruritus). This guideline addresses patients presenting with CP of different including unknown origin. If the underlying cause is detected, disease-specific guidelines should be consulted (e.g. atopic dermatitis (AD), cholestatic pruritus) (Misery, Alexandre et al. 2007, Magerl, Borzova et al. 2009, Darsow, Wollenberg et al. 2010).

According to the IFSI classification, the aetiology of CP is classified as I “dermatological”, II “systemic”, III “neurological”, IV “somatoform”, V “mixed origin” and VI “others” (Stander, Weisshaar et al. 2007). The IFSI classification comprises a clinical distinction of patients with I pruritus on primarily diseased/inflamed skin, II pruritus on normal skin and III pruritus with chronic secondary scratch lesions. Somatoform pruritus is defined as pruritus where psychiatric and psychosomatic factors play a critical role in the initiation, intensity, aggravation or persistence of the pruritus. It is best diagnosed using positive and negative diagnostic criteria (Misery, Alexandre et al. 2007).

3 Epidemiology of chronic pruritus

Data on the prevalence of CP is very limited. The prevalence of CP seems to increase with age (Rea, Newhouse et al. 1976), but epidemiological studies are missing. It is estimated that about 60% of the elderly (above 65 years of age) suffer from mild to severe occasional pruritus each week (Zylicz, Twycross et al. 2004), entitled senile pruritus or pruritus in the elderly. A population-based cross-sectional study in 19,000 adults showed that about 8-9% of the general population experienced acute pruritus, which was a dominant symptom across all age groups (Dalgard, Svensson et al. 2004). Moreover, it was revealed that pruritus is strongly associated with chronic pain (Dalgard, Dawn et al. 2007). Recent surveys indicate a point-prevalence of CP to be around 13,5% in the general adult population (Matterne, Apfelbacher et al. 2011, Matterne, Apfelbacher et al. 2013) and 16,8% in employees seeking detection cancer screenings (Stander, Schafer et al. 2010).
The 12-month-prevalence of CP was 16.4% and its lifetime prevalence 22.0% in a German population-based cross-sectional study (Matterne, Apfelbacher et al. 2011). All these data suggest a higher prevalence of CP in the general population than previously reported (Matterne, Apfelbacher et al. 2011). For the first time, a recent study found a 12 months cumulative incidence of CP of 7% (Matterne, Apfelbacher et al. 2013). This was significantly associated with age. Multivariate analysis revealed eczema, dry skin, asthma, and liver diseases, an elevated body mass index and higher anxiety scores as determinants of prevalent CP (Matterne, Apfelbacher et al. 2013).

CP may be due to both dermatological and systemic diseases. However, the origin of pruritus is unknown in 8-15% of affected patients (Weisshaar and Dalgard 2009). The frequency of pruritus among patients with a primary rash depends on the skin disease. For example, pruritus is present in all patients with AD and urticaria (Yosipovitch, Goon et al. 2002), and about 80% of psoriatic patients (Szepietowski, Reich et al. 2002, Szepietowski, Reich et al. 2004). Systemic diseases such as primary biliary cirrhosis (PBC) and CKD are associated with CP in 80-100% and 40-70%, respectively (Szepietowski and Salomon 2004). In patients with Hodgkin’s lymphoma, pruritus is a frequent symptom, occurring in more than 30% of patients with Hodgkin’s disease.

Only few studies have addressed the frequency of pruritus in primary care. According to the Australian BEACH Program, a continuous national study of general practice activity, pruritus was the presenting complaint for 0.6% of consultations, excluding perianal, periorbital or auricular pruritus (Britt, Pan et al. 2004). In Britain, the fourth national study of morbidity statistics from general practice (McCormick, Fleming et al. 1995) was conducted in 1991/1992 with 502,493 patients (1% sample of England and Wales), resulting in 468,042 person-years-at-risk. Pruritus and related conditions was present in 1.04% of consultations (male 0.73%, female 1.33%). On Crete, where patients with cutaneous disorders mostly present to hospitals rather than to primary care, PUO was diagnosed in 6.3% of 3,715 patients in 2003 (Symvoulakis, Krasagakis et al. 2006). In Germany and the Netherlands, the prevalence of pruritus as a consultation reason in primary care resulted in approximately 0.7% of all consultations, most of them with a skin disease as diagnosis (SESAM2 study from

4 The clinical picture of chronic pruritus

4.1.1 Pruritus in inflamed skin and non-inflamed skin
CP may occur as a common symptom in patients with dermatoses with primary skin lesions and systemic diseases without primary skin lesions. In systemic diseases, the skin may appear normal or have skin lesions induced by scratching or rubbing. In this case, a diagnosis might be difficult to establish. Systemic diseases frequently accompanied by pruritus are summarised in table 1. In some cases, pruritus may precede the diagnosis of the underlying disease by years. In the past years, several mechanisms of pruritus on inflamed and normal skin have been identified. In the following paragraphs some frequent patient populations and systemic diseases inducing CP are presented.

4.1.2 Pruritus in kidney disease
The pathophysiology of CKD-associated pruritus is unknown. Implicated mechanisms have included direct metabolic factors like increased concentrations of divalent ions (calcium, magnesium), parathyroid hormone (PTH), histamine and tryptase, dysfunction of peripheral or central nerves, the involvement of opioid receptors (µ- and κ-receptors) and xerosis cutis (dry skin) have been suggested as likely candidates (Blachley, Blankenship et al. 1985, Stockenhuber, Sunder-Plassmann et al. 1987, Stahle-Backdahl, Hagermark et al. 1989, Peer, Kivity et al. 1996, Pauli-Magnus, Mikus et al. 2000, Dugas-Breit, Schopf et al. 2005, Wikstrom, Gellert et al. 2005, Duque, Thevarajah et al. 2006, Kimmel, Alscher et al. 2006). New data point to a possible role of micro-inflammation which is quite frequent in uraemia (Mettang, Pauli-Magnus et al. 2002, Kimmel, Alscher et al. 2006).

4.1.3 Pruritus in hepatic diseases
In patients with cholestasis due to mechanical obstruction, metabolic disorders or inflammatory diseases, CP is a frequent symptom (Bergasa 2005). It may be quite severe and can even precede the diagnosis of e.g. PBC by years (Bergasa, Mehlman et al. 2000). In patients with infective liver disease (hepatitis B or C) or toxic liver disease (e.g. alcohol-induced), pruritus is less frequent. Hepatic pruritus
is often generalised, affecting palms and soles in a characteristic way (Cacoub, Poynard et al. 1999). One hypothesis for the mechanism of hepatic pruritus suggests that high opioid tone influences neurotransmission (Bergasa 2005). Successful treatment with µ-receptor opioid antagonists such as nalmefene supports this hypothesis (Bergasa, Schmitt et al. 1998). It has recently been shown that increased serum autotaxin levels (enzyme that metabolizes lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA)) and thereby increased LPA levels are specific for pruritus of cholestasis, but not for other forms of systemic pruritus (Kremer, Dijk et al.). Rifampicin significantly reduced itch intensity and ATX activity in pruritic patients. The beneficial antipruritic action of rifampicin may be explained partly by PXR (pregnane X receptor PXR)-dependent transcription inhibition of ATX expression (Kremer, Dijk et al.).

4.1.4 Pruritus in metabolic and endocrine diseases
In endocrine disorders as hyperthyroidism and diabetes mellitus, less than 10% of patients report pruritus (Neilly, Martin et al. 1986, Jabbour 2003). In patients with hypothyroidism, pruritus is most probably driven by xerosis of the skin. Patients with primary hyperparathyroidism do complain about itch in a substantial number of cases (Caravati, Richardson et al. 1969). The pathophysiology of pruritus in primary hyperparathyroidism is not known. These patients often experience a lack of vitamin D and minerals (e.g. zinc etc.) which probably contributes to CP. Iron deficiency is frequently associated with pruritus (Adams 1989). The mechanism for this is unknown. Iron overload as in hemochromatosis may lead to CP (Nestler 1983, Hamilton and Gould 1985).

4.1.5 Pruritus in malignancy
Several malignant disorders including tumours, bone marrow diseases and lymphoproliferative disorders may be accompanied by pruritus. In addition to toxic products generated by the tumour itself, allergic reactions to compounds released, and a direct affection on the brain or nerves (in brain tumours) may be the underlying mechanism (Bernhard 1994, Zylicz, Twycross et al. 2004). In polycythemia vera (PV), more than 50% of patients suffer from pruritus (Egli, Wieczorek et al. 1988, Diehn and Tefferi 2001). Aquagenic pruritus with pinching sensations after contact with water is a characteristic but not necessary feature. It has been suggested that high levels of histamine released by the augmented
numbers of basophilic granulocytes might trigger the itch (Gilbert, Warner et al. 1966). For polycythemia vera this seems to be most pronounced in patients showing the JAK2 617V mutation (Pieri, Bogani et al. 2009). Pruritus in Hodgkin’s disease often starts on the legs and is most severe at night, but generalised pruritus soon ensues. Several factors such as secretion of leukopeptidases and bradykinine, histamine release and high IgE levels with cutaneous depositions may contribute to pruritus in lymphoma (Krajnik and Zylicz 2001). Patients with carcinoid syndrome may experience pruritus in addition to flushing, diarrhoea and cardiac symptoms (Brunner 1995).

4.1.6 Pruritus in infectious diseases
Some generalized infections are accompanied by pruritus. Above all, patients infected with HIV may develop a pruritic papular eruption or eosinophilic folliculitis. These entities are easily diagnosed by inspection and histology of the skin and have a high positive predictive value (Gelfand and Rudikoff 2001, Eisman 2006). Whether toxocariasis infections lead to pruritus in a substantial number of patients remains to be confirmed (Afifi, Aubin et al. 2004).

4.1.7 Pruritus in neurological diseases
Multiple sclerosis, brain infarction and brain tumours are rarely accompanied by pruritus (Adreev and Petkov 1975, Canavero, Bonicalzi et al. 1997). Localised pruritus suggests a neurological origin such as compression of the peripheral or central afferences. This neuropathic origin of localized CP can be found e.g. in postzosteric pruritus, notalgia paraesthetica and brachioradial pruritus, where an underlying spinal damage is likely (Savk, Savk et al. 2000, Goodkin, Wingard et al. 2003, Savk and Savk 2005, Marziniak, Phan et al. 2011).

4.1.8 Drug induced chronic pruritus
Almost every drug may induce pruritus by various pathomechanisms (Table 2) (Reich, Stander et al. 2009). Some may cause urticarial or morbilliform rashes presenting with acute pruritus. Furthermore, drug-induced hepatotoxicity or cholestasis as well as drugs leading to xerosis or phototoxicity may produce CP on normal skin (Kaplan 1984). Hydroxyethyl starch, a compound used for fluid restoration, can induce chronic generalised or localised pruritus (Metze, Reimann et al. 1997).
4.2 Specific patient populations

4.2.1 Chronic pruritus in the elderly
Only a small number of studies have investigated pruritus in the elderly. They are characterised by selection bias and differing end points (pruritic skin disease or itch). An American study of cutaneous complaints in the elderly identified pruritus as the most frequent accounting for 29% of all complaints (Beauregard and Gilchrest 1987). A Turkish study in 4,099 elderly patients found that pruritus was the most common skin symptom with 11.5% affected. Women were more frequently affected (12.0%) than men (11.2%). Patients older than 85 years showed the highest prevalence (19.5%) and pruritus was present more frequently in winter months (12.8%) (Yalcin, Tamer et al. 2006). In a Thai study, pruritic diseases were the most common skin complaint (41%) among the elderly, while xerosis was identified as the most frequent ailment (38.9%) in a total of 149 elderly patients (Thaipisuttikul 1998). The exact mechanisms of CP in the elderly are unknown. Pathophysiological changes of the aged skin, decreased function of the stratum corneum, xerosis cutis, co-morbidities and polypharmacy may all contribute to its aetiology (Sommer, Hensen et al. 2007).

4.2.2 Chronic pruritus in pregnancy
There are no epidemiological studies assessing the prevalence of CP in pregnancy. Pruritus is the leading dermatological symptom in pregnancy estimated to occur in about 18% of pregnancies (Weisshaar, Diepgen et al. 2005). Pruritus is the leading symptom of the specific dermatoses of pregnancy such as polymorphic eruption of pregnancy (PEP), pemphigoid gestationis (PG), intrahepatic cholestasis of pregnancy (ICP), atopic eruption of pregnancy (AEP), but may also occur in other dermatoses coinciding by chance with pregnancy or in pre-existing dermatoses (Holmes 1988, Weisshaar, Diepgen et al. 2005, Ambros-Rudolph, Mullegger et al. 2006, Girling 2006). PEP is one the most common gestational dermatoses, affecting about one in 160 pregnancies. While PG, PEP and ICP characteristically present in late pregnancy, AEP starts in 75% of cases before the third trimester (Ambros-Rudolph, Mullegger et al. 2006, Weisshaar and Dalgard 2009).
ICP is characterised by severe pruritus without any primary skin lesions, but secondary skin lesions occur due to scratching. It is more prevalent among native
Indians in Chile (27.6%) and Bolivia (13.8%) depending on ethnic predisposition and dietary factors (Reyes, Gonzalez et al. 1978, Reyes, Taboada et al. 1979). ICP has decreased in both countries, e.g. to 14% in Chile. ICP is more common in women of advanced maternal age, multiple gestations, personal history of cholestasis on oral contraceptives and during winter months. Scandinavian and Baltic countries are also more affected (1-2%). In Western Europe and North America, ICP is observed in in 0.4-1% of pregnancies (Reyes, Gonzalez et al. 1978, Reyes, Taboada et al. 1979, Clark, Dwarakanath et al. 1999).

The use of topical and systemic treatments depends on the underlying aetiology of pruritus and the stage and status of the skin. Because of potential effects on the fetus, the treatment of pruritus in pregnancy requires prudent consideration of whether the severity of the underlying disease warrants treatment and selection of the safest treatments available. Systemic treatments such as systemic glucocorticosteroids, a restricted number of antihistamines and Ultraviolet phototherapy e.g. UVA may be necessary in severe and generalized forms of CP in pregnancy.

4.2.3 Chronic pruritus in children

There are no epidemiological studies assessing the prevalence of CP in children (Weisshaar, Diepgen et al. 2005, Weisshaar and Dalgard 2009). Differential diagnosis of CP in children has a wide spectrum (Weisshaar, Diepgen et al. 2005) but is dominated by AD. The cumulative prevalence of AD is between 5 to 22% in developed countries. The German Atopic Dermatitis Intervention Study (GADIS) showed a significant correlation between the pruritus intensity and severity of AD and sleeplessness (Staab, Diepgen et al. 2006, Weisshaar, Diepgen et al. 2008). A Norwegian cross-sectional questionnaire-based population study in adolescents revealed a pruritus prevalence of 8.8%. Pruritus was associated with mental distress, gender, sociodemographic factors, asthma, rhinoconjunctivitis and eczema (Halvorsen, Dalgard et al. 2009). Itching of mild to moderate severity may occur in acne (Lim, Chan et al. 2008, Reich, Trybucka et al. 2008).

There are no studies about systemic causes of CP among children. It must be assumed that systemic causes in children are mostly based on genetic diseases or systemic diseases, e.g. biliary atresia or hypoplasia, familial hyperbiliurbinemia syndromes, polycystic kidney disease. Drug-induced pruritus without any specific skin symptoms appears to be rare in children (Weisshaar and Dalgard 2009).
Common medications associated with CP in adults play a minor role in children due to limited use at that age.

When considering treatment, the physician must remember that topically applied drugs may cause intoxication due to the different body volume/body surface area rate. In addition, the licensed age for the drug must be taken into account. Low-(class 1, 2) to medium-strength (class 3) glucocorticosteroids may be applied in children. Topical immunomodulators are used for AD and pruritus in children aged 2 years and older but in some European countries e.g. pimecrolimus is licensed for use in children older than 3 months. Topical capsaicin is not used in children < 10 years. The dosages of systemic drugs need to be adapted in children. Ultraviolet phototherapy should be performed with caution due to possible long-term photo damage of the skin.

5. Diagnostic management

5.1 Patient's history, examination and clinical characteristics of pruritus

The patient's history and clinical examination are crucial when they present with, as it is an assessment of their pruritus including intensity, onset, time course, quality, localisation, triggering factors and the patient's theory of causality. Attention should be paid to incidents preceding or accompanying the onset of pruritus (e.g. pruritus following bathing). It is also important to consider the methods used to relieve pruritus, e.g. brushes. This helps with the interpretation of clinical findings such as the absence of secondary skin lesions in the mid-back known as the “butterfly sign” which indicates that the patient cannot reach this area by hand and is thus unable to scratch it. It is also important to ask about pre-existing diseases, allergies, atopic diathesis and drug intake (table 2). A great deal of helpful information can be obtained using questionnaires. There are no definite clinical findings related to specific pruritic diseases (Weisshaar, Apfelbacher et al. 2006), but awareness of the following anamnestic aspects and clinical findings may help with the diagnosis of the cause of pruritus:

- When several family members are affected, scabies or other parasites should be considered.
- The relationship between pruritus and special activities is important: Pruritus during physical activity is suggestive of cholinergic pruritus. It is
common in patients with atopic eczema and mild forms of cholinergic pruritus. Pruritus provoked by skin cooling after bathing should prompt consideration of aquagenic pruritus. It may be associated or precede PV or myelodysplastic syndrome, and screening for these diseases should be performed intermittently.

- Nocturnal generalised pruritus associated with chills, fatigue, tiredness and “B” symptoms (weight loss, fever and nocturnal sweating) raises the possibility of Hodgkin’s disease.
- Somatoform pruritus rarely disturbs sleep; most other pruritic diseases cause nocturnal wakening.
- Seasonal pruritus frequently presents as “winter itch”, which may also be the manifestation of pruritus in the elderly due to xerosis cutis and astematotic eczema.

A patient’s history should always include all current and recent medications infusions and blood transfusions. Severe pruritus can lead to considerable psychological distress. This should not be underestimated by the physician and should be addressed directly. CP can be accompanied by behavioural/adjustment disorder and a withdrawal from social and work life (Schneider, Driesch et al. 2006). In these cases, psychosomatic counselling is required. CP with excoriations sometimes progressing to self-mutilation can be caused by psychiatric disease such as delusional parasitosis. Such patients need psychiatric examination and if necessary treatment. A solely psychological cause of pruritus should not be diagnosed without psychiatric examination.

Examination of patients with CP includes a thorough inspection of the entire skin including mucous membranes, scalp, hair, nails and anogenital region. The distribution of primary and secondary skin lesions should be recorded together with skin signs of systemic disease. General physical examination should include palpation of the liver, kidneys, spleen and lymph nodes.

There is no standardised method of documenting pruritus. The sensation of pruritus is subject to much inter- and intra-individual variation due to tiredness, anxiety, stress. Questionnaires deliver self-reported information regarding various aspects of CP. So far, no structured questionnaire exists, but the questionnaire should consider the patients’ perspective, the medical doctors’ perspective and needs of various measurements of clinical trials. Several different questionnaires
in different languages for different pruritic diseases have been developed, but so far no definite questionnaires exist. Additional tools are needed to better assess the different dimensions of CP and better tailor management. With this goal in mind, a special interest group (SIG) was initiated by members of the IFSI to determine which of the various psychometric properties of CP questionnaires offer the greatest utility in the evaluation of CP (Weisshaar, Gieler et al. 2012). The intensity of pruritus is usually assessed by scales such as the visual analogue scale (VAS) or the numeric rating scale (Phan, Blome et al. 2011, Reich, Heisig et al. 2011). When using a VAS, the scale ranges from 0 – 10 and is graphically presented as a bar chart. However, these methods often fail to consider the frequency of itch attacks over the course of a day. For patients with severe PUO, it can be helpful to keep a diary in order to allow for clearer attribution of the symptoms.

5.2 Diagnostic algorithm and Diagnostics
Laboratory screening, clinical and technical approaches and investigations are summarised in Table 3 and Table 4. All this helps to follow a diagnostic algorithm (Table 5).

6. Therapy

6.1 Therapy: General principles
In the patient with CP it is important to establish an individual therapy regimen according to their age, pre-existing diseases, medications, quality and intensity of pruritus. Most importantly, elderly patients, pregnant women and children need special attention. As the care of patients with CP often extends over a long period, with initial uncertainty about the origin of their pruritus, frustration regarding the failure of past therapies and general psychological stress frequently occurs. The diagnostic procedures and therapy should be discussed with the patient in order to achieve best possible concordance and compliance. It must be remembered that some therapies are not licensed for CP and can only be prescribed “off-label”. This requires separate informed consent.

First, the patient should be informed about general pruritus-relieving measures (Table 6). They include simple and helpful measures such as wet and cold wraps, application of lotio alba etc. Application of short-time localized heat has shown
promising itch-relieving results in case reports and an experimental study (Pfab, Valet et al. 2010). Prior to further symptomatic therapy, the patient should be subject to a careful diagnostic evaluation and therapy given for any underlying disease (Tables 3, 4). If pruritus still persists, combined or consecutive step-by-step symptomatic treatment is necessary (Table 12). Pharmacologic interventions for specific pruritic diseases, e.g. urticaria should be performed according to the guideline of the specific disease and the field’s Cochrane Group (Zuberbier, Bindslev-Jensen et al. 2006, EASL 2009).

6.2 Causative therapy and etiology specific treatment

CP can be addressed by treating the underlying disease. Therapeutic measures include specific treatments of underlying dermatoses, avoidance of contact allergens, discontinuation of implicated drugs, specific internal, neurological and psychiatric therapies, surgical treatment of an underlying tumour or transplantation of organs. Normally, there is sudden relief of pruritus when the underlying disease improves, e.g. when Hodgkin’s disease responds to chemotherapy or when a patient with PBC has been transplanted. For some underlying diseases, specific treatments have proven to be successful in relieving pruritus, even if the underlying disease is not treated. Etiology specific treatments act on a known or hypothetically assumed pathogenesis of pruritus in underlying diseases. For only a few of these treatments evidence of efficacy can be found in controlled studies. Treatments for CP in specific diseases are presented in Tables 7-11. When deciding the choice of treatment, consideration should be given to the level of evidence, side-effects, practicability, costs, availability of a treatment and individual factors such as patient’s age.

6.3 Symptomatic therapy: topical

6.3.1 Local anaesthetics

Local anaesthetics act via different groups of skin receptors. They can be used for pain, dysaesthesia and pruritus. Benzocaine, lidocaine, pramoxine as well as a mixture of prilocaine and lidocaine are widely used topically, but only have a short-term effect. In experimental studies, the antipruritic effect of local anaesthetics is limited in diseased skin e.g. AD (Weisshaar, Heyer et al. 1996, Weisshaar, Forster...
et al. 1997). Successful application in the treatment of localised forms of pruritus such as notalgia paraesthesia has been reported (Layton and Cotterill 1991, Weisshaar, Heyer et al. 1996). When treating larger skin areas, polidocanol 2-10% in different galenic formulations can be used, frequently in combination with 3% urea. There are no controlled clinical trials investigating the antipruritic effects of local anaesthetics.

**Expert recommendation:** Short-term application of topical local anaesthetics can be recommended as an additional therapy. The risk of sensitization can be considered as low.

### 6.3.2 Glucocorticosteroids

Pruritus experimentally induced by histamine was significantly suppressed by topical hydrocortisone when compared to placebo (Zhai, Frisch et al. 2000). All other clinical studies apply to an underlying inflammatory dermatosis in which "pruritus" was one parameter amongst many. Clinical experience shows that topical glucocorticosteroids can be effective if itch is the consequence of an inflammatory dermatosis. Use of topical glucocorticosteroids to treat the symptom of pruritus is not advised in the absence of an inflammatory dermatosis. Topical glucocorticosteroids with a favourable side-effect profile (e.g. fluticasonepropionate, methylprednisolon-aceponate or mometasonfuorate) are to be preferred (Al-Ghnaniem, Short et al. 2007, Szczepanowska, Reich et al. 2008). In some cases the anti-inflammatory effect of glucocorticosteroids is helpful, but insufficient to completely abolish pruritus (Kawashima, Tango et al. 2003).

**Expert recommendation:** Initial short-term application of topical glucocorticosteroids can be recommended in CP associated with an inflammatory dermatosis, but should not be used as long-term treatment or in the absence of a primary rash.

### 6.3.3 Capsaicin

Capsaicin (trans-8-metyl-N-vanillyl-6-nonamamide) is the pungent agent of chilli peppers and is used as a pain-relieving medication (Szolcsanyi 2004). Topical application of capsaicin activates sensory C-fibres to release neurotransmitters inducing dose-dependent erythema and burning. After repeated applications of capsaicin, the burning fades due to tachyphylaxis and retraction of epidermal nerve fibers (Szolcsanyi 2004). However, pruritus reoccurs some weeks after
discontinuation of therapy indicating no permanent degeneration of the nerve fibers (Wallengren and Hakanson 1992).

The greater the initial dose of capsaicin and the more frequent the applications, the sooner the desensitization will appear and pruritus disappear. Severe initial burning may be a side-effect of topical application. Cooling of the skin can also reduce the capsaicin-evoked burning. More unusual adverse effects of capsaicin include cough or sneezing due to inhalation of capsaicin from the skin or from the jar and its effect on sensory nerve fibres in the mucous membranes (Szolcsanyi 2004). It appears that such adverse effects are less bothersome for patients with severe pruritus compared to patients with slight pruritus (unpublished observations). A lower concentration of capsaicin and less frequent applications will induce tachyphylaxis later but may give a better compliance. The concentration of capsaicin varies in different studies, but 0.025% capsaicin is tolerated well by most patients. If capsaicin is not available in this concentration as a standard drug it can be produced using a lipophilic vehicle. Capsaicin is also well soluble in alcohol; capsaicin 0.025% in spir dil can be used to treat itchy scalp (not published). A weaker concentration of 0.006% capsaicin is recommended for intertriginous skin e.g. pruritus ani (Lysy, Sistiery-Ittah et al. 2003).


**Expert recommendation:** Capsaicin can be effective in localized forms of CP, but patient compliance due to side-effects can restrict usage.
6.3.4. Cannabinoid receptor agonists

Topical cannabinoid receptor agonists are a new development since 2003 and appear to have antipruritic and analgesic properties. Experimentally induced pain, pruritus and erythema could be reduced by application of a topical cannabinoid agonist (Dvorak, Watkinson et al. 2003, Rukwied, Watkinson et al. 2003). One cosmetic product containing the cannabinoid receptor and peroxisome proliferator-activated receptor alpha (PPAR-α) agonist N-palmitoylethanolamine is currently on the market. In (non-vehicle controlled) clinical trials and case series, it proved to have antipruritic effects in prurigo, AD, CKD-associated pruritus and PUO (Szepietowski, Szepietowski et al. 2005, Stander, Reinhardt et al. 2006, Eberlein, Eicke et al. 2008) as well as analgetic effects in postzosteric neuralgia (Phan, Siepman et al. 2010).

**Expert recommendation:** Cannabinoid receptor agonists can be effective in the treatment of localized pruritus.

6.3.5 Tacrolimus and Pimecrolimus

The effects of tacrolimus and pimecrolimus on pruritus are mediated both through their immunological and neuronal properties (Stander and Luger 2003). Paradoxically, while they can induce transient pruritus at the beginning of treatment, in the medium-term they may provide an alternative treatment for many causes of pruritus. They are very effective against pruritus in AD (Fleischer and Boguniewicz 2010). Furthermore, tacrolimus ointment is more effective at reducing pruritus when compared with vehicle and pimecrolimus cream (Fleischer and Boguniewicz 2010). Clinical trials have shown benefit of both pimecrolimus and tacrolimus in seborrhoeic dermatitis, genital lichen sclerosus, intertriginous psoriasis and cutaneous lupus erythematosus and – only for tacrolimus – in resistant idiopathic pruritus ani (Simpson and Noble 2005, Wollina, Hansel et al. 2006, Barikbin, Givrad et al. 2009, Goldstein, Creasey et al. 2011, Kuhn, Gensch et al. 2011, Papp, Papp et al. 2011, Ang-Tiu, Meghrajani et al. 2012, Suys 2012). In other diseases, the available data are limited to small case series, or individual cases e.g. hand eczema (pimecrolimus), rosacea (tacrolimus), graft-versus-host disease (tacrolimus), vulval pruritus (tacrolimus) or Netherton’s syndrome (tacrolimus, pimecrolimus). Topical tacrolimus has been shown anecdotally to be effective in pruritus associated with systemic diseases such as PBC (Aguilar-Bernier, Bassas-Vila et al. 2005) and chronic renal insufficiency (Pauli-Magnus,
Klumpp et al. 2000, Kuypers, Claes et al. 2004). However, these observations have not been confirmed in a controlled study on CKD-associated pruritus (Duque, Yosipovitch et al. 2005, Ghorbani, Feily et al. 2011). Both substances can be used to treat localised forms of CP such as genital pruritus (Stander, Schurmeyer-Horst et al. 2006).

**Expert recommendation:** Tacrolimus and pimecrolimus are effective in localised forms of CP.

### 6.3.6 Acetylsalicylic Acid
Topical acetylsalicylic acid (acetylsalicylic acid/dichlormethane solution) has been described to have antipruritic effects in occasional patients with lichen simplex (Yosipovitch, Sugeng et al. 2001). However, this beneficial effect could not be confirmed in experimentally induced itch with histamine (Thomsen, Benfeldt et al. 2002).

**Expert recommendation:** Due to the lack of studies, topical acetylsalicylic acid can currently not be recommended for CP.

### 6.3.7 Doxepin
The tricyclic antidepressant doxepin showed antipruritic effects when applied as a 5% cream in double-blind studies for treatment of AD (Drake, Fallon et al. 1994), lichen simplex, nummular dermatitis and contact dermatitis (Drake and Millikan 1995). Topical doxepin therapy is not licensed and not used in any European country except for the UK (Xepin©) (Greenberg 1995, Shelley, Shelley et al. 1996, Bonnel, La Grenade et al. 2003).

**Expert recommendation:** Due to the increased risk of contact allergy, especially when the treatment exceeds eight days, topical doxepin cannot be recommended.

### 6.3.8 Zinc, Menthol and Camphor
Although zinc oxide has been used in dermatology for over 100 years due to its anti-inflammatory, antiseptic and anti-pruritic properties and its safety, there is only scarce literature on its effects. Prescriptions of zinc are frequent, with concentrations varying from 10 to 50% in creams, liniments, lotions, ointments and pastes that are useful in the treatment of pruritus, especially for localised forms of pruritus, in children as well as in adults (Welsh 1955).
Menthol is an alcohol obtained from mint oils, or prepared synthetically. Applied to the skin and mucous membranes, it causes a sensation of coldness, followed by an analgesic effect (Welsh 1955). Menthol is used in dusting powders, liniments, lotions and ointments in concentrations from one to 10% (Welsh 1955). Menthol binds to the TRPM8 receptor (Green and Schoen 2007) which belongs to the same TRP family of excitatory ion channels as TRPV1, the capsaicin receptor. These two receptors have been shown to co-exist occasionally in the same primary afferent neurons and promote thermosensations at a wide range of temperatures 8-28°C and >50°C respectively (Green and Schoen 2007). Short-term application of such medications in CP in combination with other topical or systemic therapies can be recommended.

Camphor is an essential oil containing terpenes, it is soluble in alcohol (Welsh 1955). Applied to the skin it causes a sensation of warmth which is followed by a mild degree of anesthesia (Welsh 1955). Camphor has been used in dermatology for decades in liniments, lotions and ointments in concentrations from 2-20%. It has been shown to specifically activate another constituent of the TRP ion channel family, namely TRPV3 (Macpherson, Hwang et al. 2006). Recently, camphor was demonstrated to activate capsaicin receptor, TRPV1, while menthol also activates the camphor receptor, TRPV3. These findings illustrate the complexity of sensory perception and explain the efficacy of ointments containing both menthol and camphor (Welsh 1955).

**Expert recommendation:** Short term application of camphor, menthol and zinc in CP in combination with other topical or systemic therapies can be recommended.

### 6.3.9 Mast cell inhibitors

In a multi-center, double-blind, placebo-controlled trial, application of a 3% hydrogel formulation of tiacrilast against vehicle in AD led to no significant improvement of pruritus (Czarnetzki, Brechtel et al. 1993). Pruritus in AD responds to topical sodium cromoglycate (Haider 1977), which was proved by a recent placebo-controlled study (Stainer, Matthews et al. 2005).

**Expert recommendation:** There is limited evidence to recommend the use of topical mast cell inhibitors for CP.
6.4 Systemic Therapy

6.4.1 Antihistamines
Antihistamines are the most widely used systemic antipruritic drugs in dermatology. Most antihistamines that have been tried in pruritus belong to the H1 type. First generation antihistamines, such as chlorpheniramine, clemastine, cyproheptadine, diphenhydramine, hydroxyzine, and promethazine are known to bind not only to H1-receptors but also to muscarinic, α-adrenergic, dopamine or serotonin receptors and have a central sedative effect. Due to side effects, the application of sedative antihistamines is nowadays limited. Second generation antihistamines like cetirizine, levocetirizine, loratadine, desloratadine, ebastine, fexofenadine and rupafine have minimal activity on non-histaminic receptors, little sedative effect, and a longer duration of action compared to the first generation (O’Donoghue and Tharp 2005). Non-sedative H1-receptor antagonists offer an effective reduction of pruritus in diseases associated with increased mast cell degranulation like urticaria or mastocytosis (O’Donoghue and Tharp 2005). However, the doses required to alleviate pruritus in urticaria often amount to up to four times the licensed dose (Asero 2007). Higher doses of the second generation antihistamines enhance their soporific side effects (O’Donoghue and Tharp 2005), which may contribute to their efficacy. A recent case series suggest that updosing of antihistamines may also be beneficial in CP (Schulz, Metz et al. 2009).

Systemic H1-antihistamines are often employed to combat itch in AD, but only sedative antihistamines have shown some benefit, mainly by improving sleep (Hoare, Li Wan Po et al. 2000). Hydroxyzine is the most commonly used antihistaminic of the first generation showing sedative, anxiolytic and antipruritic activities. In adult patients it is recommended as an antipruritic agent in the dosage 75-100 mg/day. In children the effective dose is 1-2.5mg/kg/day. In a controlled study, addition of hydroxyzine resulted in a 750-fold increase in the dose of histamine required to elicit itch. There was a five-fold increase following both cyproheptadine and placebo and a ten-fold increase following diphenhydramine (Rhoades, Leifer et al. 1975). In addition, hydroxyzine was significantly more effective in reducing histamine-induced pruritus than neuroleptics, like thiothixene, chlorpromazine and thioridazine (Arnold, Simpson et al. 1979).
There is currently no high-level evidence to support or refute the efficiency or safety of oral H1 antihistamines used as a monotherapy for eczema (Apfelbacher, van Zuuren et al. 2013).

In addition, antihistamines are widely used as first-line drugs for treatment of CP associated with different systemic diseases such as chronic renal failure, cholestasis, hematopoietic diseases and thyroid disorders. However, conventional doses of antihistamines in the treatment of pruritus in internal diseases have not proven to be effective (O'Donoghue and Tharp 2005).

Although identified in human skin, H2-receptors play a minor role in pruritus, and H2-receptor antagonists alone have no antipruritic effect (Paul and Bodeker 1986, Hoare, Li Wan Po et al. 2000). A combination of H2-antihistamines and H1-antihistamines has been used in treatment of pruritus in small trials but the results are conflicting (Paul and Bodeker 1986, Hoare, Li Wan Po et al. 2000). A combination of H1-antihistamine with a leukotriene antagonist has been reported to alleviate pruritus in chronic urticaria (Nettis, Colanardi et al. 2004).

**Expert recommendation:** Antihistamines are effective in treating CP in urticaria. Antihistamines are of some value for itch in AD and CP of diverse origin. As there is limited evidence of antipruritic effects of non-sedating antihistamines in AD, PV and CP of diverse origin, sedating antihistamines can be recommended to be applied during night time for sleep improvement. Hydroxyzine is the first choice of the majority of physicians trying to control CP but its sedative effect may contraindicate its use in the elderly.

### 6.4.2 Mastcell inhibitors

Ketotifen, a mast cell stabilizer, showed antipruritic effects in single patients with CKD-associated pruritus (Francos, Kauh et al. 1991). Two patients with CKD-associated pruritus (Rosner 2006) and Hodgkin’s lymphoma (Leven, Naysmith et al. 1977) showed a significant antipruritic effect with the mast cell stabilizer cromoglicic acid.

**Expert recommendation:** There is insufficient evidence to recommend the systemic use of mast cell inhibitors for CP.
6.4.3 Glucocorticosteroids

There are no studies investigating the efficacy of the exclusive use of systemic glucocorticosteroids in CP. In clinical experience, pruritus ceases within approximately 30 minutes of i.v. glucocorticosteroids in the treatment of urticaria or drug-induced exanthema. Likewise, in AD, allergic contact dermatitis, dyshidrosis and bullous pemphigoid, rapid reduction of pruritus is observed, which can be explained by the high anti-inflammatory potency of glucocorticosteroids. Thus, while systemic glucocorticosteroids should not be considered as an antipruritic for long-term therapy, short-term use is possible in cases of severe pruritus, but should not be prescribed for a period of more than two weeks (Streit, Von Felbert et al. 2002) because of severe side-effects.

Prednisone is the most commonly selected oral corticosteroid initially at a daily dose which can range from 2.5 mg to 100 mg daily or more, usually starting in a dose of 30-40 mg daily. In exceptional cases, i.v. methylprednisolone is used at a dose of 500 mg to 1 g per day, because of its high potency and low sodium-retaining activity. It is important to remember that the dosage should be tapered in accordance with the severity of pruritus. Before discontinuing systemic therapy one may change to topical corticosteroid therapy. Corticosteroids should be used with caution in children and the elderly as well as in patients with relevant metabolic disorders such as diabetes.

**Expert recommendation:** Systemic corticosteroids can be used as short-term treatment in severe cases of CP, but should not be used for longer than 2 weeks.

6.4.4 Opioid receptor agonists and antagonists

Experimental and clinical observations have demonstrated that pruritus can be evoked or intensified by endogenous or exogenous mu-opioids (Fjellner and Hagermark 1982). This phenomenon can be explained by activation of spinal opioid receptors, mainly µ-opioid receptors. Reversing this effect with µ-opioid antagonists thus leads to an inhibition of pruritus (Phan, Siepmann et al. 2010). The opposite is true for kappa-opioids. Their binding to κ-opioid receptors leads to inhibition of pruritus (Phan, Lotts et al. 2012).

Several clinical studies have demonstrated that different µ-opioid receptor antagonists may significantly diminish pruritus (Bergasa, Talbot et al. 1992, Bergasa, Alling et al. 1995, Wolfhagen, Sternieri et al. 1997, Bergasa, Schmitt et
al. 1998, Bergasa, Alling et al. 1999, Bergasa 2005, Phan, Bernhard et al. 2012). In double-blind RCT, μ-opioid receptor antagonists such as nalmefine, naloxone and naltrexone have exhibited high antipruritic potency. For example, pruritus in chronic urticaria, AD, and cholestatic pruritus has shown therapeutic response to nalmefene (10 mg twice daily) and naltrexone (50 - 100 mg /day) (Banerji, Fox et al. 1988, Monroe 1989). Controlled studies have also been performed in patients with CKD-associated pruritus (Peer, Kivity et al. 1996, Ghura, Patterson et al. 1998, Pauli-Magnus, Mikus et al. 2000). Results were variable from significant reduction of pruritus to no response. Case reports have demonstrated efficacy in prurigo nodularis, macular amyloidosis, lichen amyloidosis, pruritus in mycosis fungoides, psoriasis vulgaris, aquagenic pruritus, hydroxylethyl starch induced pruritus and PUO.

Nalfurafine, a preferential κ-opioid receptor agonist, was investigated in CKD-associated CP in two large RTCs (Wikstrom, Gellert et al. 2005, Kumagai, Ebata et al. 2010). Both trials demonstrated significant clinical benefit of nalfurafine in patients with uremic pruritus (Phan, Lotts et al. 2012) within the first seven days of treatment. The drug is currently licensed in Japan only.

**Expert recommendation:** Opioid receptor antagonists may be effective in cholestatic pruritus and AD but their side-effect profile needs to be considered. Nalfurafine can be applied in Japanese patients with uremic pruritus.

### 6.4.5 Gabapentin and Pregabalin

Gabapentin is an antiepileptic drug, also used in neuropathic disorders causing pain or pruritus (Misery 2005). The mechanisms of action of gabapentin, a 1-amino-methyl-cyclo-hexane acetic acid and a structural analogue of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) remain unclear. It is used in postherpetic neuralgia (Argoff, Katz et al. 2004), especially with paroxysmal pain or pruritus. Anecdotal indications are brachioradial pruritus (Kanitakis 2006) and cutaneous T-cell lymphoma (Demierre and Taverna 2006). Pilot studies have been performed for the treatment of pruritus caused by burns and wound healing in children demonstrating antipruritic effects of gabapentin (Mendham 2004). Double-blind, randomized, placebo-controlled trials were performed for CKD-associated pruritus (Gunal, Ozalp et al. 2004) and cholestatic pruritus (Bergasa, McGee et al. 2006). Gabapentin was safe and effective for treating CKD-associated pruritus.
(Vila, Gommer et al. 2008, Razeghi, Eskandari et al. 2009). Pregabalin is similar to gabapentin and a more recent drug. Its use has been suggested in a case of cetuximab-related pruritus, aquagenic pruritus and in CKD patients unable to tolerate gabapentin (Porzio, Aielli et al. 2006) (Ehrchen and Stander 2008) (Rayner, Baharani et al. 2012). A recent controlled trial demonstrated a significant antipruritic effect of pregabalin in patients on hemodialysis within one month (Aperis, Paliouras et al. 2010).

**Expert recommendation:** Gabapentin and pregabalin can be recommended in the treatment of CKD-associated pruritus and neuropathic CP.

### 6.4.6 Antidepressants

Psycho-emotional factors are known to modulate the ‘itch threshold.’ Under certain circumstances, they can trigger or enhance CP (Paus, Schmelz et al. 2006). Itch is a strong stressor and can elicit psychiatric disease and psychological distress. Depressive disorders are present in about 10% of patients with CP (Schneider, Driesch et al. 2006). Consequently, depressive symptoms are treated in these patients, and some antidepressants also exert an effect on pruritus through their pharmacological action on serotonin and histamine. SSRIs, such as paroxetine, can have an antipruritic effect on patients with PV, psychogenic or paraneoplastic pruritus and other patients with chronic PUO (Zylicz, Krajnik et al. 2003). Tricyclic antidepressants, like mirtazapine (Davis, Frandsen et al. 2003) and especially doxepin (Shohrati, Tajik et al. 2007) have been effective in urticaria, AD and HIV-related pruritus.

The SSRI paroxetine (20 mg/d) has exhibited antipruritic effects in pruritus due to PV (Tefferi and Fonseca 2002), paraneoplastic pruritus (Zylicz, Smits et al. 1998, Weisshaar 2008) and psychiatric disease (Biondi, Arcangeli et al. 2000). In two patients, pruritus was induced by discontinuation of paroxetine treatment for depression (Mazzatenta, Peonia et al. 2004). A RCT in pruritus of non-dermatologic origin confirmed the antipruritic effect of paroxetine (Zylicz, Krajnik et al. 2003). In a two-armed proof-of-concept study with paroxetine and fluvoxamine, patients with CP of dermatological origin reported significant antipruritic effect (Stander, Bockenholt et al. 2009). Sertralin proved efficacy in cholestatic pruritus as demonstrated in a RCT (Mayo, Handem et al. 2007). As severe cardiac side effects have been described, especially in the elderly this therapy should be used...
with caution. A psychosomatic/psychiatric examination before starting the treatment is recommended because of its stimulative effects.

**Expert recommendation:** SSRIs can be recommended for the treatment of somatoform pruritus, paraneoplastic CP, PUO and cholestatic pruritus. Mirtazapine can be recommended in CP of AD.

### 6.4.7 Serotonin receptor antagonists

Due to the pathophysiological significance of serotonin in different diseases such as kidney and liver diseases, serotonin receptor antagonists (of the 5-HT3 type) such as ondansetron (8 mg 1-3x/d), topisetron (5 mg/d) and granisetron (1 mg/d) have been used anecdotally to treat pruritus (Schworer and Ramadori 1993, Schworer and Ramadori 1993, Raderer, Muller et al. 1994, Andrews, Quan et al. 1995, Schworer, Hartmann et al. 1995, Jones 1999, Albares, Betlloch et al. 2003). Contradictory or negative results have been reported in partly controlled studies using ondansetron for cholestatic pruritus (Schworer, Hartmann et al. 1995, O'Donohue, Haigh et al. 1997, Muller, Pongratz et al. 1998) and opioid-induced pruritus (Larijani, Goldberg et al. 1996, Borgeat and Stirnemann 1999, Kjellberg and Tramer 2001). An antipruritic effect was reported for ondansetron in CKD-associated pruritus (Balaskas, Bamihas et al. 1998). However, this could not be confirmed in subsequent controlled studies (Ashmore, Jones et al. 2000, Murphy, Reaich et al. 2003, Weisshaar, Dunker et al. 2004) later on.

**Expert recommendation:** Due to the lack of convincing evidence, serotonin receptor antagonists cannot be recommended in the treatment of CP.

### 6.4.8 Thalidomide

A number of mechanisms for the antipruritic action of thalidomide have been proposed including a central depressant effect (Daly and Shuster 2000), a local effect on proliferated neural tissue in PN (van den Broek 1980), and the antagonism of TNF-alpha (Arrese, Dominguez-Soto et al. 2001). The best results with thalidomide in CP have been achieved in PN. Several studies have shown a rapid decrease of pruritus on thalidomide (50 - 300 mg per day) (Winkelmann, Connolly et al. 1984, Johnke and Zachariae 1993). A prospective open trial of thalidomide 100 mg per day, followed by narrow-band UVB (TL-01) showed a high response with minimal side-effects (Ferrandiz, Carrascosa et al. 1997). Likewise, good results have been seen in HIV-positive...
patients with PN (Maurer, Poncelet et al. 2004). There is one randomized double-blind cross-over trial of the successful treatment of CKD-associated pruritus with thalidomide (Silva, Viana et al. 1994). Thalidomide is teratogenic and there is a dose-related risk of neuropathy, especially in high daily doses (> 100 mg/d) (Gaspari 2002).

**Expert recommendation:** Though there is evidence for its antipruritic effect, thalidomide is not recommended for the treatment of CP due to its side effects.

**6.4.9 Leukotriene receptor antagonist, TNF-alpha antagonists**

Leukotriene receptor antagonists (e. g. montelukast) and TNF-alpha antagonists influence the pathogenesis of AD. They have been used in combination with antihistamines as antipruritic therapy. Montelukast has also been used in several types of urticaria as well as in combination with antihistamines. A combination of H1-antihistamine with a leukotriene antagonist has been reported to alleviate pruritus in chronic urticaria (Daly and Shuster 2000).

**Expert recommendation:** Due to the lack of evidence, leukotriene receptor antagonists and TNF-alpha antagonists cannot be recommended in the treatment of CP.

**6.4.10 Ciclosporin A**

Pruritus in AD responds to treatment with ciclosporin A as demonstrated in controlled double-blind studies (van Joost, Stolz et al. 1987, Wahlgren, Scheynius et al. 1990). Ciclosporin A has been administered in PN for 24 to 36 weeks, using doses of 3.0-4.5 mg/kg per day. Improvement was observed in both pruritus and skin lesions after two weeks of treatment (Berth-Jones, Smith et al. 1995, Siepmann, Luger et al. 2008). It seems likely that in these diseases ciclosporin A acts on pruritus through its immunological effects. However, direct effects on nerve endings are also possible, suggested by successful use in non-immunological diseases as reported in several studies, e. g. ten patients with senescent pruritus were treated with ciclosporin A 5mg/kg per day for eight weeks (Teofoli, De Pita et al. 1998). All patients of this uncontrolled, open study responded. Case reports describe antipruritic effects in dystrophic epidermolysis bullosa associated CP and in CKD-associated pruritus (Calikoglu and Anadolu 2002, Fusaro, Munaretto et al. 2004).
Expert recommendation: Ciclosporin A can be recommended in the treatment of CP in AD or in PN.

6.4.11 Aprepitant
Substance P (SP) has a dominant role in pruritus induction in the skin. Via binding to the neurokinin 1 receptor (NKR1) on keratinocytes, blood vessels and mast cells, SP promotes inflammation and mast cell degranulation. SP is released from sensory neurons. In conditions with hyperplasia of skin nerves (AD, PN), SP levels are increased. Accordingly, inhibition of the pruritogenic effects of SP by blocking the corresponding receptor may have antipruritic effects. Several case reports suggest a positive role of the NKR1 receptor antagonist aprepitant in CP e.g. cutaneous T-cell lymphoma, solid tumors and drug-induced pruritus (Vincenzi, Fratto et al. 2010, Vincenzi, Tonini et al. 2010, Booken, Heck et al. 2011, Torres, Fernandes et al. 2012). Recently, a proof-of-concept study in 20 patients showed significant, antipruritic effects in chronic, therapy-refractory pruritus of various origins with a one week monotherapy of aprepitant (Stander, Siepmann et al. 2010). The highest response rate was observed in patients with atopic diathesis and PN. Randomized controlled studies are missing.

Expert recommendation: NKR1 antagonists, in particular aprepitant, are promising substances in the therapy of CP. Aprepitant might be used as a second-line option in therapy refractory cases, e.g. patients with AD and PN.

6.5 UV Phototherapy
Ultraviolet (UV)-based therapy is well established for treating pruritus and utilizes UVB (290–320 nm) and UVA (320–400 nm). The light sources include broadband UVB (BB-UVB, 290–320 nm, peaks at 313 nm), narrowband UVB (NB-UVB, 311 nm), broadband UVA (320–400 nm, peaks at 355 nm), and UVA1 (340–400 nm, peaks at 365 nm) (Rivard and Lim 2005).
Inflammatory dermatoses associated with pruritus respond well to different UV-treatments including UVB 311: For the treatment of AD, early studies demonstrated that UVB was better than placebo (Jekler and Larko 1988). In a recent study NB-UVB was better than BB-UVA and both were better than placebo (Reynolds, Franklin et al. 2001). In the treatment of pruritus of AD, BB-UVB and UVA were equally effective in a half-body comparison (Jekler and Larko 1991). In
a more recent study, NB-UVB was insignificantly better than UVA1 for pruritus (Legat, Hofer et al. 2003). In AD, phototherapy seems to act locally rather than systemically: When one half of the body was treated with UVB and the other half was not, only the treated side improved (Jekler and Larko 1988).

For the treatment of prurigo PUVA, UVA1 and NB-UVB proved to be effective in a randomised controlled trial, with PUVA and UVA1 superior to NB-UVB (Gambichler, Hyun et al. 2006).

For many other skin diseases, a number of studies have demonstrated the efficacy of UV-treatment, e.g. psoriasis, lichen planus, T-cell lymphoma, solar, chronic, and idiopathic urticaria, and urticaria pigmentosa.

It can be assumed that in cases of pruritic inflammatory dermatoses pruritus is reduced by inhibiting pro-inflammatory mediators and induction of anti-inflammatory and immunosuppressive factors. UVB mainly affects epidermal keratinocytes and Langerhans cells, due to its limited penetration into the skin. UVA1, in contrast, reaches to the dermis and therefore can affect T lymphocytes, mast cells, and dermal dendritic cells, e.g. induces apoptosis of these cells (Rivard and Lim 2005). However, UV-B-induced apoptosis of mast cells has been argued to explain relief of pruritus (Szepietowski, Morita et al. 2002). Furthermore, phototherapy leads to a reduction of CGRP-immunoreactive nerve fibres in the skin (Wallengren and Sundler 2004).

In conditions with pruritus on primarily non-inflamed skin, UV-therapy has been particularly effective in CKD-associated pruritus (Saltzer and Grove 1975, Gilchrest, Rowe et al. 1977). In a placebo-controlled trial, UVA alone was ineffective for this condition (Taylor, Taylor et al. 1983). However, an antipruritic effect was seen in CKD-associated pruritus when treated with combined UVA/UVB phototherapy (Berne, Vahlquist et al. 1984). BB-UVB alone was effective in treating CKD-associated pruritus. It was remarkable that in spite of placebo control (only one body half was treated) an improvement of pruritus occurred over the entire body (Gilchrest, Rowe et al. 1979), suggesting a systemic antipruritic effect. In an open pilot study using NB-UVB 14/20, CKD-associated pruritus patients responded well to treatment (Ada, Seckin et al. 2005). Also in a recent study NB-UVB appeared to be effective in reduction of CKD-associated pruritus (Seckin, Demircay et al. 2007). However in another case NB-UVB treatment was unsuccessful, but BB-UVB helped (Hsu and Yang 2003).
UV therapy has also been reported to be effective in a number of cases of metabolic itch. In PV, 8/10 patients responded to NB-UVB in an open study (Baldo, Sammarco et al. 2002). Aquagenic pruritus has shown response to bath PUVA therapy (Jahn, von Kobyletzki et al. 1997) and systemic PUVA (Martinez-Escribano, Quecedo et al. 1997) for the duration of therapy. To treat aquagenic pruritus, PUVA was found to be superior to BB-UVB in 5 patients (Menage, Norris et al. 1993). Recently, two patients with aquagenic pruritus have been reported with a good, but ephemeral response to NB-UVB (Xifra, Carrascosa et al. 2005).

In HIV patients with pruritus, UVB produced significant relief of pruritus in an open study with 21 patients (33% primary pruritus, 66% eosinophilic folliculitis) (Lim, Vallurupalli et al. 1997). In a single case report, a patient with Hodgkin’s disease responded well to BB-UVB (Kaptanoglu and Oskay 2003).

A retrospective analysis of children up to the age of 18 years suffering from AD and psoriasis suggests NB-UVB treatment (Pavlovsky, Baum et al. 2011). In children, longer follow-up is essential to determine true carcinogenic risk of UV therapy.

**Expert recommendation:** UV therapy can be applied for CP. The mode of UV phototherapy depends on the underlying disease. UVA as well as UVB (NB-UVB / BB-UVB) as well as a combination of UVA/UVB relieve CP in certain diseases. UV phototherapy can be used in combination with topical and/or systemic treatment except for calcineurin inhibitors and immunosuppressant drugs.

### 6.6 Psychosomatic therapy (Relaxation techniques and psychotherapy)

The vicious itch-scratch cycle has to be taken into account when a patient is treated for pruritus. In addition to causal and symptomatic therapy, behavioural therapy to avoid scratching should be considered, e.g. conscious suppression of the reflex by intense concentration, distraction or alternative scratching techniques such as habit reversal (Rosenbaum and Ayllon 1981). This is very important in patients with prurigo nodularis who might show an unconscious automatic scratching behaviour.

Adjuvant psychosocial programmes are most effective in AD (Gieler, Kupfer et al. 2000, Staab, von Rueden et al. 2002, Stangier, Ehlers et al. 2004, Weisshaar, Diepgen et al. 2008). Such programmes include strategies for breaking the vicious circle of itching and scratching, relaxation and stress management techniques as
well as strategies for dealing with relapses. A similar educational programme was developed for patients with CP (Bathe, Mattern et al. 2009, Evers, Duller et al. 2009). It is currently established for in-patient hospital treatment of patients with pruritic dermatoses using behavioural therapy in the context of an integrated psychosomatic treatment (Hoegl, Fichter et al. 1998, Lange, Zschocke et al. 1999). In patients with coexisting depression, psychotherapy in combination with psychotropic medication can be helpful even to treat pruritus of different etiology (Gupta 1995). Most publications on psychotherapeutic/ psychopharmacologic interventions, however, refer to small groups or single case reports. In neurotic excoriations, combined psychopharmacotherapy is also often indicated (Phillips and Robson 1988, Gupta 1995, Arnold, Auchenbach et al. 2001, Phillips 2002).

**Expert recommendation:** Relaxation techniques and education programmes for CP patients are useful as a complementary treatment for managing CP.

### 7. Key summary of discussion concerning country-specific procedures

- **Antihistamines:** Sedative H1 antihistamines are first-choice therapy in CP to improve night-time sleep. Studies on application of higher doses are as yet to be conducted.
- **UV Phototherapy** is recommended for generalized pruritus, especially in elderly pruritus patients or in case of contraindications for systemic therapy.
- **Anticonvulsants/pain modulators** are recommended in neuropathic pruritus.
- **Antidepressants** are recommended in forms of CP not responding to other therapies.
- **Systemic glucocorticosteroids** are not recommended for treatment of CP except of very severe and desperate cases.
- **Serotonin receptor antagonists** and thalidomide are not recommended for treatment.

**Acknowledgement**

We thank Erika Schulz and Dr. Reginald Scheidt very much for their great help and assistance in the preparation of this manuscript.
Table 1: Systemic diseases that can induce pruritus (examples)

| Metabolic and endocrine diseases | o Chronic renal insufficiency  
| | o Liver diseases with or without cholestasis  
| | o Hyperparathyroidism  
| | o Hyper- and hypothyroidism  
| | o Iron deficiency  
| Infective diseases | o HIV and AIDS  
| | o Parasitoses including Helminthosis  
| Haematological disorders | o Polycythemia vera, myelodysplastic syndrome  
| | o Lymphoma e.g. Hodgkin lymphoma  
| Neurological diseases | o Multiple sclerosis  
| | o Brain tumors  
| | o Notalgia paresthetica  
| | o Brachioradial pruritus  
| | o Postzosteric neuralgia  
| Psychiatric or psychosomatic diseases | o depression  
| | o affective disorders  
| | o hallucinosis  
| | o obsessive and compulsory disorders  
| | o schizophrenia  
| | o eating disorders  

Table 2: Drugs that may induce or maintain chronic pruritus (without a rash)

<table>
<thead>
<tr>
<th>Class of drug</th>
<th>Substance (examples)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE inhibitors</td>
<td>captopril, enalapril, lisinopril</td>
</tr>
<tr>
<td>Antiarrhythmic agents</td>
<td>amiodarone, disopyramide, flecainide</td>
</tr>
<tr>
<td>Antibiotics</td>
<td>amoxicillin, ampicillin, cefotaxime, ceftriaxone, chloramphenicol, ciprofloxacin,</td>
</tr>
<tr>
<td></td>
<td>clarithromycin, clindamycin, cotrimoxazole, erythromycin, gentamycin, metronidazole,</td>
</tr>
<tr>
<td></td>
<td>minocycline, ofloxacin, penicillin, tetracycline</td>
</tr>
<tr>
<td>Antidepressivants</td>
<td>amitriptylin, citalopram, clomipramin, desipramine, doxepin, fluoxetine, fluvoxamine,</td>
</tr>
<tr>
<td></td>
<td>imipramine, lithium, maprotiline, mirtazapine, nortriptyline, paroxetine, sertraline</td>
</tr>
<tr>
<td>Antidiabetic drugs</td>
<td>glimepiride, metformin, tolbutamide</td>
</tr>
<tr>
<td>Antihypertensive drugs</td>
<td>clonidine, doxazosin, hydralazine, methyldopa, minoxidil, prazosin, reserpine</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>carbamazepine, clonazepam, gabapentin, lamotrigine, phenobarbital, phenytoin, topiramate, valproic acid</td>
</tr>
<tr>
<td>Anti-inflammatory drugs</td>
<td>acetylsalicylic acid, celecoxib, diclofenac, ibuprofen, indometacin, ketoprofen, naproxen, piroxicam</td>
</tr>
<tr>
<td>AT II antagonists</td>
<td>Irbesartan, telmisartan, valsartan</td>
</tr>
<tr>
<td>Betablockers</td>
<td>acebutolol, atenolol, bisoprolol, metoprolol, nadolol, pindolol, propranolol</td>
</tr>
<tr>
<td>Bronchodilators, mucolytic agents, respiratory stimulans</td>
<td>aminophylline, doxapram, ipratropium bromide, salmeterol, terbutaline</td>
</tr>
<tr>
<td>Calcium antagonists</td>
<td>amlodipine, diltiazem, felodipine, isradipine, nifedipine, nimodipine, nisoldipine, verapamil</td>
</tr>
<tr>
<td>Diuretics</td>
<td>amiloride, furosemide, hydrochlorothiazide, spironolactone, triamterene</td>
</tr>
<tr>
<td>Hormones</td>
<td>clomifene, danazol, oral contraceptives, estrogens, progesterone, steroids, testosterone and derivates, tamoxifen</td>
</tr>
<tr>
<td>Immunosuppressive drugs</td>
<td>cyclophosphamide, ciclosporin, methotrexate, mycophenolatmofetil, tacrolimus (up to 36%), thalidomide</td>
</tr>
<tr>
<td>Antilipids</td>
<td>clofibrate, fenofibrate, fluvastatin, lovastatin, pravastatin, simvastatin</td>
</tr>
<tr>
<td>Neuroleptics</td>
<td>e. g. chlorpromazine, haloperidol, risperidone</td>
</tr>
<tr>
<td>Plasmaexpanders, blood supplying drugs</td>
<td>Hydroxyethylstarch, pentoxifylline</td>
</tr>
<tr>
<td>Tranquilizers</td>
<td>alprazolam, chloridiazepoxid, lorazepam, oxazepam, prazepam</td>
</tr>
<tr>
<td>Uricostatics</td>
<td>allopurinol, colchicine, probenecid, tioproprin</td>
</tr>
</tbody>
</table>
### Table 3: Diagnostics: laboratory screening, diverse approaches and investigations

| Chronic pruritus: First-step lab screening | • Differential blood cell count, ESR  
• Blood urea nitrogen, creatinine  
• Alkaline phosphatase, liver enzymes  
• Bilirubine  
• T3, T4, TSH  
• Glucose  
• Serum iron, Ferritin  
• Age > 40 y: stool occult blood |
| Chronic pruritus: further investigations | • Immunelectrophoresis  
• Hepatitis serology, Cholesterol, Triglycerides  
• Parathormone  
• Erythrocyte-Fluorescence (EPP)  
• Biopsy with DIF (mastocytosis, pemphigoid etc.)  
• Swab for candida (mucocutaneous pruritus)  
• Urine: mast cell metabolites  
• Further imaging studies and bone marrow investigation for mastocytosis |
| Chronic pruritus: approach I | • Detailed history: preceding skin changes?  
• Weight loss, fever, fatigue  
• Emotional stress?  
• Medication? Drug abuse?  
• Subtle primary skin disorders: xerosis, scabies  
• Physical examination  
• Bath oil, emollient / education  
• Follow-up appointment in 2 weeks |
| Chronic pruritus: approach II | • Detailed history renewed  
• Lab screening (see above and Table 4)  
• Detailed general physical examination: LN, rectal  
• Stool for parasites  
• Chest X-ray  
• Biopsy  
• Complete internist work-up, further imaging  
• Follow-up |
Table 4: Laboratory and technical investigations in chronic pruritus due to systemic diseases

<table>
<thead>
<tr>
<th>Laboratory and technical screening-basic</th>
<th>Creatinine, AST, ALT, alkaline phosphatase, bilirubin, TSH, complete blood count, glucose, chest X-ray, (Ca, y-GT, stool test for parasites in genito-anal pruritus)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolic and endocrine diseases</td>
<td></td>
</tr>
<tr>
<td>Renal insufficiency</td>
<td>Lab I.: Creatinine, (and urea for elderly)</td>
</tr>
<tr>
<td></td>
<td>Lab II: phosphate, PTH, HCO3, urinalysis, urine protein concentration. ANA, anti-ds-DNS-Ab, ANCA's, Anti-GBM-Ab etc.</td>
</tr>
<tr>
<td></td>
<td>Tech: sonography of the kidneys, CT or MRI</td>
</tr>
<tr>
<td>Liver diseases with or without cholestasis</td>
<td>Lab I: y-GT, AP, bilirubin, AST,ALT, (and HB-, HC-antibodies, if a risk-patient)</td>
</tr>
<tr>
<td></td>
<td>Lab II: LDH, AMA, ANA, Anti-HBc-Ab, HBs-Ag, Anti-HCV-Ab, anti-smooth muscle Ab, antiaetin Ab</td>
</tr>
<tr>
<td></td>
<td>Tech: sonography of the liver, CT or MRT, (Magnetic resonance cholangiogram (MRC) or endoscopic retrograde cholangiogram (ERC) to rule out primary sclerosing cholangitis)</td>
</tr>
<tr>
<td>Hyperparathyroidism</td>
<td>Lab I: PTH, Calcium (only, if symptoms or signs of hyperparathyroidism (“stones, bones, moans and abdominal groans and psychiatric overtones”)</td>
</tr>
<tr>
<td></td>
<td>Lab II: phosphate, Vit D (1,25-Vit D, 25 Vit-D)</td>
</tr>
<tr>
<td></td>
<td>Tech: sonography of the parathyroid glands, scintigraphy, MRI</td>
</tr>
<tr>
<td>Hyper- and hypothyroidism</td>
<td>Lab I: TSH, Lab II: T3, T4, MAKs and TRAKs</td>
</tr>
<tr>
<td></td>
<td>Tech: sonography of the thyroid glands, iodine-scintigraphy</td>
</tr>
<tr>
<td>Anemia</td>
<td>Lab I: complete blood count including MCV and MCHC, LDH</td>
</tr>
<tr>
<td></td>
<td>Lab II: ferritin, transferrin saturation (TSAT)– optionally: Lab III: Bone marrow aspiration with iron staining</td>
</tr>
<tr>
<td>Iron deficiency</td>
<td>Lab I: ferritin</td>
</tr>
<tr>
<td></td>
<td>Lab II: transferrin saturation (TSAT)</td>
</tr>
<tr>
<td>Malabsorption</td>
<td>(Lab-tests only in case of a typical history (pancreas disease, intestinal resection) or symptoms like chronic diarrhea or steatorrhea and weight loss.</td>
</tr>
<tr>
<td></td>
<td>Lab I: Serum protein, serum albumine, calcium, blood count, gliadin-antibody</td>
</tr>
<tr>
<td></td>
<td>Lab II: Vitamin A (hyperkeratosis by Vitamin A deficiency), Vitamin B12 (neuropathy by Vitamin B deficiency)</td>
</tr>
<tr>
<td></td>
<td>Tech: endoscopy with biopsy</td>
</tr>
<tr>
<td>Other diseases</td>
<td>Pruritus of the elderly</td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>Lab I: Lab screening: creatinine, ALT, AST, alkaline phosphatase, bilirubin, TSH, full blood count, + BUN, (+ estimated creatinine clearance )</td>
</tr>
<tr>
<td>Infective diseases</td>
<td>HIV</td>
</tr>
<tr>
<td></td>
<td>HIV-antibodies, Westernblot</td>
</tr>
<tr>
<td></td>
<td>Parasitoses including Helminthosis, Giardia lamblia (rare)</td>
</tr>
<tr>
<td></td>
<td>stool culture and microscopic examination</td>
</tr>
<tr>
<td>Haematological disorders</td>
<td>Polycythemia vera</td>
</tr>
<tr>
<td></td>
<td>Lab I: blood count, thrombocytes, sedimentation rate,</td>
</tr>
<tr>
<td></td>
<td>Lab II: to rule out secondary erythrocytosis: O2 saturation,</td>
</tr>
<tr>
<td></td>
<td>erythropoietin (EPO) level (renal cell carcinoma or polycystic kidneys)</td>
</tr>
<tr>
<td></td>
<td>Lab III: bone marrow with chromosomal aberrations,</td>
</tr>
<tr>
<td></td>
<td>Tech: sonography, CT or MRI of the spleen,</td>
</tr>
<tr>
<td></td>
<td>Lymphoma</td>
</tr>
<tr>
<td></td>
<td>Lab I: blood count, blood smear, thrombocytes, sedimentation rate,</td>
</tr>
<tr>
<td></td>
<td>Lab II: Bone marrow with chromosomal aberrations,</td>
</tr>
<tr>
<td></td>
<td>Tech: sonography, CT or MRI of the abdomen, thorax and additional affected areas, (PET)</td>
</tr>
<tr>
<td>Neurological diseases</td>
<td>Multiple sclerosis</td>
</tr>
<tr>
<td></td>
<td>Lab : cerebrospinal fluid analysis (oligoclonal bands?)</td>
</tr>
<tr>
<td></td>
<td>Tech: EEG, MRI, CT of the brain und functional tests</td>
</tr>
<tr>
<td></td>
<td>Brain tumors</td>
</tr>
<tr>
<td></td>
<td>Lab: cerebrospinal fluid analysis with histopathology</td>
</tr>
<tr>
<td></td>
<td>Tech: EEG, MRI, CT of the brain</td>
</tr>
<tr>
<td></td>
<td>Notalgia paresthetica</td>
</tr>
<tr>
<td></td>
<td>MRI of the thoracic spine</td>
</tr>
<tr>
<td></td>
<td>Brachioradial pruritus</td>
</tr>
<tr>
<td></td>
<td>MRI of the thoracic and cervical spine</td>
</tr>
<tr>
<td>Psychiatric or psychosomatic diseases</td>
<td>Psychiatric and psychosomatic exploration, psychiatric short questionnaire for depressive and anxiety disorder</td>
</tr>
<tr>
<td>Pregnancy with or without cholestasis</td>
<td>Lab I: y-GT, AP, bilirubin, AST, ALT, bile acids</td>
</tr>
<tr>
<td></td>
<td>Lab II: Virus screen: hepatitis A,B,C, Epstein Barr and cytomegalovirus, a liver autoimmune screen for chronic active hepatitis and primary biliary cirrhosis (anti-smooth muscle and antimitochondrial antibodies) (Girling 2006)</td>
</tr>
<tr>
<td></td>
<td>Tech: liver ultrasound</td>
</tr>
<tr>
<td>Drug induced pruritus</td>
<td>Lab I: y-GT, AP, bilirubin, AST; ALT, LDH</td>
</tr>
<tr>
<td></td>
<td>Skin biopsy in case of HES exposition (electron microscopy).</td>
</tr>
</tbody>
</table>
Table 5: Diagnostic algorithm

Patient with CP

Any pathological findings on the skin, e.g. dermatoses?

Are the lesions present/visible when itch occurs?

Itch on primary diseased skin

Chronic scratch lesions

Itch on primary normal skin

Detailed history:
Duration of itch, quality, localization
Preceding skin changes?
Weight loss, fever, fatigue
Emotional stress?
Medication? Drug abuse?

Itch dermatosis

Prurigo nodularis
Lichen simplex

PUO

Evalution of Skin disease

Detailed history:
Duration of itch, quality, localization
Preceding skin changes?
Weight loss, fever, fatigue
Emotional stress?
Medication? Drug abuse?

Any pathologic parameters?

Laboratory tests:
Specific laboratory test part II
Chest X-ray

Disease-specific further evaluations.
Symptomatic and causative treatment

Prurigo nodularis
Lichen simplex

PUO

Detailed history:
Duration of itch, quality, localization
Preceding skin changes?
Weight loss, fever, fatigue
Emotional stress?
Medication? Drug abuse?

Internal disease?

Drugs?

Change drugs

Any pathologic parameters?

Laboratory tests:
Specific laboratory test part II
Chest X-ray

Disease-specific further evaluations.
Symptomatic and causative treatment

Detailed history:
Duration of itch, quality, localization
Preceding skin changes?
Weight loss, fever, fatigue
Emotional stress?
Medication? Drug abuse?

Internal disease?

Drugs?

Change drugs

Any pathologic parameters?

Laboratory tests:
Specific laboratory test part II
Chest X-ray

Disease-specific further evaluations.
Symptomatic and causative treatment

Detailed history:
Duration of itch, quality, localization
Preceding skin changes?
Weight loss, fever, fatigue
Emotional stress?
Medication? Drug abuse?

Internal disease?

Drugs?

Change drugs

Any pathologic parameters?

Laboratory tests:
Specific laboratory test part II
Chest X-ray

Disease-specific further evaluations.
Symptomatic and causative treatment

Detailed history:
Duration of itch, quality, localization
Preceding skin changes?
Weight loss, fever, fatigue
Emotional stress?
Medication? Drug abuse?

Internal disease?

Drugs?

Change drugs

Any pathologic parameters?

Laboratory tests:
Specific laboratory test part II
Chest X-ray

Disease-specific further evaluations.
Symptomatic and causative treatment

Detailed history:
Duration of itch, quality, localization
Preceding skin changes?
Weight loss, fever, fatigue
Emotional stress?
Medication? Drug abuse?

Internal disease?

Drugs?

Change drugs

Any pathologic parameters?

Laboratory tests:
Specific laboratory test part II
Chest X-ray

Disease-specific further evaluations.
Symptomatic and causative treatment

Detailed history:
Duration of itch, quality, localization
Preceding skin changes?
Weight loss, fever, fatigue
Emotional stress?
Medication? Drug abuse?

Internal disease?

Drugs?

Change drugs

Any pathologic parameters?

Laboratory tests:
Specific laboratory test part II
Chest X-ray

Disease-specific further evaluations.
Symptomatic and causative treatment

Detailed history:
Duration of itch, quality, localization
Preceding skin changes?
Weight loss, fever, fatigue
Emotional stress?
Medication? Drug abuse?
### Table 6: General measures for treating chronic pruritus

<table>
<thead>
<tr>
<th>Avoidance of</th>
<th>Factors that foster dryness of the skin, as e. g. dry climate, heat (e. g. sauna), alcoholic compresses, ice packs, frequent washing and bathing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact with irritant substances (e.g. compresses with rivanol, chamomile, tea-tree oil)</td>
<td></td>
</tr>
<tr>
<td>Very hot and spicy food, large amounts of hot drinks and alcohol</td>
<td></td>
</tr>
<tr>
<td>Excitement, strain, negative stress</td>
<td></td>
</tr>
<tr>
<td>In atopic patients: avoidance of aerogen allergens (e. g. house dust resp. house dust mites) which may aggravate pruritus</td>
<td></td>
</tr>
<tr>
<td>Avoidance of</td>
<td>mild, non-alcaline soaps, moisturizing syndets and shower / bathing oils</td>
</tr>
<tr>
<td>Application of</td>
<td>Luke-warm water, bathing time not exceeding 20 minutes. In patients with dermatoses: after contact with water, the skin should be dabbed dry without rubbing it because damaged and inflamed skin might worsen</td>
</tr>
<tr>
<td>soft clothing permeable to air, e.g. cotton, silver based textiles</td>
<td></td>
</tr>
<tr>
<td>Skin moisturizer on a daily basis especially after showering and bathing</td>
<td></td>
</tr>
<tr>
<td>Topicals with symptomatic relief especially for pruritus at night: creams/lotions / sprays with e.g. urea, campher, menthol, polidocanol, tannin preparations wet, cooling or fat-moist-wrappings, wrappings with black tea, short and lukewarm showers</td>
<td></td>
</tr>
<tr>
<td>Relaxation techniques</td>
<td>Autogenic training, relaxation therapy, psychosocial education</td>
</tr>
<tr>
<td>Education</td>
<td>coping with the vicious circle of itch-scratch-itch educational training programs e.g. for children suffering from atopic dermatitis or chronic pruritus(Staab, Diepgen et al. 2006, Weisshaar, Diepgen et al. 2008, Bathe, Matterne et al. 2009)</td>
</tr>
</tbody>
</table>
Table 7: Therapeutic options in CKD-associated pruritus

<table>
<thead>
<tr>
<th>Therapeutic options in renal pruritus</th>
<th></th>
</tr>
</thead>
</table>
| **Antipruritic effects confirmed in controlled studies** | - Activated charcoal 6g/d (Bernhard 1994)  
- Gabapentin 300 mg 3 x/week postdialysis (Gunal, Ozalp et al. 2004)  
- Gamma-linolenic acid cream 3x/d (Chen, Chiu et al. 2006)  
- Capsaicin 3-5x/d (Breneman, Cardone et al. 1992, Tarng, Cho et al. 1996)  
- UVB phototherapy (Gilchrest, Rowe et al. 1979)  
- Acupuncture at the Quchi (LI11) acupoint (Che-Yi, Wen et al. 2005)  
- Nalfurafine intravenously postdialysis (Wikstrom, Gellert et al. 2005)  
- Thalidomide 100 mg/d (Silva, Viana et al. 1994) |
| **Equivocal effects in controlled studies** | - Naltrexone 50 mg/d (Peer, Kivity et al. 1996, Pauli-Magnus, Mikus et al. 2000)  
- Ondansetron 8 mg orally or i.v. (Ashmore, Jones et al. 2000, Murphy, Reaich et al. 2003) |
| **Antipruritic effects confirmed in case reports** | - Cholestyramine (Bernhard 1994)  
- Tacrolimus ointment 2x/d (Pauli-Magnus, Klumpp et al. 2000, Kuypers, Claes et al. 2004)  
- Cream containing structured physiological lipids with endocannabinoids (Szepietowski, Szepietowski et al. 2005)  
- Mirtazapine (Davis, Frandsen et al. 2003)  
- Cromolyn sodium (Rosner 2006)  
- Erythropoetin 36 IU/kg KG 3x/week (De Marchi, Cecchin et al. 1992)  
- Lidocaine 200 mg i.v./d (Bernhard 1994)  
- Ketotifen 1-2 mg/d (Francos, Kauh et al. 1991) |
### Table 8: Therapeutic options in hepatic and cholestatic pruritus

<table>
<thead>
<tr>
<th>Therapeutic options in hepatic and cholestatic pruritus</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antipruritic effects confirmed in controlled studies</strong></td>
</tr>
<tr>
<td>- Cholestyramine 4-16 g/d (not in primarily biliary cirrhosis!) (Bergasa, Mehlman et al. 2000)</td>
</tr>
<tr>
<td>- Ursodesoxycholic acid 13-15 mg/kg/d (Goulis, Leandro et al. 1999)</td>
</tr>
<tr>
<td>- Rifampicin 300-600 mg/d (Ghent and Carruthers 1988); Kremer, van Dijk 2012)</td>
</tr>
<tr>
<td>- Naltrexone 50 mg/d (Wolfhagen, Sternieri et al. 1997, Terg, Coronel et al. 2002)</td>
</tr>
<tr>
<td>- Naloxone 0,2 µg/kg KG/min (Bergasa, Alling et al. 1995)</td>
</tr>
<tr>
<td>- Nalmefene 20 mg 2x/d (Bergasa, Alling et al. 1999)</td>
</tr>
<tr>
<td>- Sertraline 75-100 mg/d (Mayo, Handem et al. 2007)</td>
</tr>
<tr>
<td>- Thalidomide 100 mg/d (McCormick, Scott et al. 1994)</td>
</tr>
<tr>
<td><strong>Equivocal effects in controlled studies</strong></td>
</tr>
<tr>
<td>- Ondansetron 4 mg or 8 mg i.v. or 8 mg orally (Schworer and Ramadori 1993, O'Donohue, Haigh et al. 1997, Muller, Pongratz et al. 1998)</td>
</tr>
<tr>
<td><strong>Antipruritic effects confirmed in case reports</strong></td>
</tr>
<tr>
<td>- Phenobarbital 2-5 mg/kg KG/d (Raiford 1995)</td>
</tr>
<tr>
<td>- Stanozolol 5 mg/d (Walt, Daneshmend et al. 1988)</td>
</tr>
<tr>
<td>- Phototherapy: UVA, UVB (Fleischer 2000)</td>
</tr>
<tr>
<td>- Bright light therapy (10,000 Lux) reflected toward the eyes up to 60 min twice/d (Bergasa, Link et al. 2001)</td>
</tr>
<tr>
<td>- Etanercept 25mg sc. 2x/w (Epstein and Kaplan 2004)</td>
</tr>
<tr>
<td>- Plasma perfusion (Fleischer 2000)</td>
</tr>
<tr>
<td>- Liver transplantation (Neuberger 2003)</td>
</tr>
</tbody>
</table>
Table 9: Antipruritic therapy of atopic dermatitis

| Antipruritic effects confirmed in controlled studies: | • Glucocorticosteroids (topical and oral)  
• Ciclosporin A  
• Leukotriene antagonists (e.g. zafirlukast)  
• Interferon gamma, i.c.  
• Tacrolimus ointment (2x/d)  
• Pimecrolimus cream (2x/d)  
• Doxepin 5% cream (2x/d) (Drake, Fallon et al. 1994, Drake and Millikan 1995) |
| --- | --- |
| Equivocal results: | • Antihistamines (topical and systemic)  
• Naltrexon 50 mg/d (Brune, Metze et al. 2004)  
• Mycophenolatemofetil |
| Antipruritic effects confirmed in case reports: | • Antipruritic effects confirmed in case reports:  
• Macrolide antibiotics  
• Immunoglobuline, i.v.  
• UVA1-/UVB 311-Therapie  
• Capsaicin (3-5x/d) |

Table 10: Therapeutic options in polycythaemia vera

<table>
<thead>
<tr>
<th>Therapeutic options in polycythaemia vera</th>
<th>Effects confirmed in case reports</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Paroxetine 20mg/d (Diehn and Tefferi 2001, Tefferi and Fonseca 2002)</td>
</tr>
<tr>
<td></td>
<td>Hydroxyzine (Diehn and Tefferi 2001)</td>
</tr>
<tr>
<td></td>
<td>Fluoxetine 10mg/d (Tefferi and Fonseca 2002)</td>
</tr>
<tr>
<td></td>
<td>Aspirin (Fjellner and Hagermark 1979)</td>
</tr>
<tr>
<td></td>
<td>Cimetidine 900mg/d (Easton and Galbraith 1978, Weick, Donovan et al. 1982)</td>
</tr>
<tr>
<td></td>
<td>Pizotifen 0.5mg 3x/d (Fitzsimons, Dagg et al. 1981)</td>
</tr>
<tr>
<td></td>
<td>Cholestyramine (Chanarin and Szur 1975)</td>
</tr>
<tr>
<td></td>
<td>Ultraviolet B phototherapy (Baldo, Sammarco et al. 2002)</td>
</tr>
<tr>
<td></td>
<td>Photochemotherapy (PUVA) (Swerlick 1985, Jeanmougin, Rain et al. 1996)</td>
</tr>
<tr>
<td></td>
<td>Transcutaneous electrical nerve stimulation (Tinegate and McLelland 2002)</td>
</tr>
</tbody>
</table>

Table 11: Therapeutic options in aquagenic pruritus

<table>
<thead>
<tr>
<th>Therapeutic options in aquagenic pruritus</th>
<th>Effects confirmed in RCT:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Topical capsaicin 0.025%-1% thrice/d for 4 weeks</td>
</tr>
</tbody>
</table>

Effects confirmed in case reports:
- Topical capsaicin 0.025%-1% thrice/d for 4 weeks
• Transdermal application of scopulamin, topically 3% or 9%
• Baths with sodium bicarbonate (0.5-1 kg/bath)
• Propranolol 10 to 80 mg/d
• Clonidine 0.1 mg twice/d
• Astemizol 10 mg/d
• Ibuprofen (prior to bathing)
• Pregabalin 150-300 mg/day
• Antihistamines, e.g. hydroxyzine 25 mg/d, chlorpheneramine 8 mg/d, cetirizine, loratadine, fexofenadine, terfinadine
• H2-blockers: cimetidine 900 mg/d
• Opioid receptor antagonists, e.g. naltrexone |
<table>
<thead>
<tr>
<th>25-50 mg/d</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Selective serotonin reuptake inhibitors, e. g. paroxetine 20 mg/d, fluoxetine 10 mg/d</td>
</tr>
<tr>
<td>• Interferon-alpha 2b 5x 3 mil IE 1st week, 3x3 mil IE 2nd – 4th week</td>
</tr>
<tr>
<td>• Acetylic salicylic acid 300-500 mg/day</td>
</tr>
</tbody>
</table>
**Table 12: Stepwise symptomatic-therapeutic approach in chronic pruritus (> 6 weeks)**

<table>
<thead>
<tr>
<th>Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Step 1</strong></td>
</tr>
<tr>
<td>- General therapeutic measures <em>(tab. 5)</em>, especially basic therapy with moisturizers</td>
</tr>
<tr>
<td>- Initial symptomatic therapy: systemic H1 antihistaminics*, topical corticosteroids</td>
</tr>
<tr>
<td><strong>Step 2</strong></td>
</tr>
<tr>
<td>- Symptomatic causative adapted therapy <em>(tab. 5-9)</em> if origin is unknown</td>
</tr>
<tr>
<td><strong>Step 3</strong></td>
</tr>
<tr>
<td>- In pruritus of unknown origin or therapy refractory cases in the 2nd step: symptomatic topical and/or systemic therapy, e.g. capsaicin, calcineurin inhibitors, cannabinoid agonists, naltrexone, gabapentin, UV photo therapy, immunosuppressives (ciclosporin)</td>
</tr>
</tbody>
</table>

**Concomitant treatment in every step**

<table>
<thead>
<tr>
<th>Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Diagnostics and treatment of underlying disease</td>
</tr>
<tr>
<td>- General therapeutic measures <em>(tab. 5)</em></td>
</tr>
<tr>
<td>- <strong>In sleep disorders</strong>: sedative H1-antihistaminics, tranquilizers, tricyclic antidepressants or neuroleptics</td>
</tr>
<tr>
<td>- Psychosomatic care, behavioural therapy for scratch behaviour</td>
</tr>
<tr>
<td>- <strong>In erosive scratch lesions</strong>: disinfecting measures, topical corticosteroids</td>
</tr>
</tbody>
</table>

* There is no evidence for the following diagnoses: cholestatic pruritus, nephrogenic pruritus
8. References


